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Since the discovery of the DNA double helix in 1953 [1], several milestones have 
marked the path of the field of genomic research. One of these was the introduction 
of Sanger sequencing in the late 1970s, which provided a novel and effective 
technique to analyze and improve our insight into the human genome [2], but the 
most significant was the completion of The Human Genome Project (HGP), 
conducted by many laboratories around the world, in 2001 [3].  
In concert with the completion of the HGP, an exciting new era of 
sequencing has begun. Driven by the technical challenge posed by the HGP, 
techniques for DNA sequencing have changed dramatically and led to the advent of 
next-generation sequencing (NGS) methods. These methods rely on the massively 
parallel sequencing of very short DNA fragments [4]. Within a relatively short 
period of time, NGS technologies have revolutionized research on the human 
genome and also that of other organisms [5] in various fields of genomics including 
DNA sequencing, expression studies through RNA sequencing (RNA-Seq) and 
epigenetic investigations (ChIP-Seq) [6,7]. 
 With respect to DNA sequencing in humans, NGS-based techniques can be 
applied to entire genomes or to select parts of the genome (exome sequencing or 
gene panels). The methods are categorized into three groups based on their sample 
preparation methodology. First, in Whole Genome Sequencing (WGS), the entire 
genome of individual humans, which is composed of 3.2 billion nucleotides, can be 
sequenced directly within a week [8]. Second, in Whole Exome Sequencing (WES) 
or gene panels in which capture-by-hybridization selectively enriches regions or 
genes of interest, followed by the sequencing procedure. WES allows sequencing all 
of ~20,000 human genes following enrichment of ~180,000 exons, in dozens of 
individuals, within a few days [8]. Based on a similar approach, dedicated disease-
specific gene panels may be used for targeted sequencing of particular gene sets of 
interest. In the third method, amplicon enrichment, genes (or regions) of interest are 
enriched by a multiplex-PCR, the products of which are then subjected to the 
sequencing procedure. This method is frequently applied for cancer genetics to 
detect causative mutations in tumour samples derived from, e.g., breast cancer [9] 
and thyroid cancer [10] patients. A simplified overview of the application of NGS 
techniques to detect/identify disease causing mutations is depicted in Figure 1. 
Importantly, introduction of NGS techniques provided unprecedented 
possibilities for genome analyses. These advances and the sharp decreases in the 
cost of sequencing technologies [12] have paved the way for widespread use of WES 
for disease-gene discovery. Miller syndrome was the first rare Mendelian disorder 
for which the causal gene was identified using WES [13]. 
  









Figure 1: A simplified workflow of a next generation sequencing analysis (adapted from Lohmann & 
Klein [11]). 1. For the sequencing analysis, DNA is required. This can be derived from large families 
with many affected patients, sporadic patients and their healthy parents (trios), cohorts of small families 
with the same disease (for gene discovery) or from individual patients or tissues (e.g. tumor samples). 
2. DNA is prepared for the sequencing by fragmentation. Specific target sequences need to be enriched 
(by hybridization or by PCR). 3. Fragments are ligated to universal adapters and amplified clonally, and 
then loaded onto a chip. 4. The sequencing reaction is monitored by a light signal (fluorescence) or by 
the release of a proton resulting in a pH change. 5. The signals are translated into a sequence and 
aligned to the reference genome. 6. Mismatches with the reference sequence are annotated with respect 
to the coding part of the genome. 7. Distinction are made between likely benign or possibly pathogenic 
variants using In silico methods such as predictor algorithms or mutation databases which 
comprehensively collect pathogenic mutations. 8. Finally, candidate variants classified as potential 
disease-causing need to be validated by Sanger sequencing along with functional studies and knockout 
animal models. 
 
Since then, the list of rare Mendelian disorders for which WES was used to 
identify the genetic causes is rapidly growing [14]. WES has also been valuable in 
identifying causal and predisposing variants in common diseases and 
complex traits such as cardiovascular diseases, obesity and diabetes, 
hypertension and cancers [15]. The rationale for applying WES is evident: the 
20,687 protein-coding genes [16] constitute only ~1% of the human genome but 
harbor about 85% of the known disease-associated mutations. In fact, most 
Mendelian disorders are caused by exonic mutations or splice-site mutations [17]. 
Accordingly, by sequencing no more than about 50Mb of our genome, the entire 
exome can be effectively analyzed. In recent years, WES has become the routine 
diagnostic application of NGS to identify the causes of mostly monogenic disorders. 
In particular, exome sequencing has helped to overcome difficulties and limitations 
in the identification of causal mutations in diseases with extreme locus heterogeneity 
such as intellectual disabilities [18], hearing loss [19] and retinitis pigmentosa [20]. 
One of the unique capabilities NGS methods offer is the detection of de novo 
variants across the entire genome by application of a trio-based sequencing strategy. 
This has unraveled the genetic cause, including identification of novel disease-
associated genes, in sporadic cases of autism [21], intellectual disability [22] and 
schizophrenia [23].  
Although WES may lead to identification of causal mutation(s), and despite 
its unique ability to detect de novo variants genome-wide, limitations of the technique 
such as incomplete capturing of all exons and the complexity of variant 
interpretation still pose challenges for application of WES in the clinic [24–26].  
 In parallel to applying WES, a broad range of dedicated gene panels have 
been implemented in germ-line and tumor diagnostics. These provide a sensitivity 
and specificity that equals the current standard of Sanger sequencing [27] and, to 
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date, outperform WES in this respect. Comprehensive gene panels also allow more 
samples to be analyzed in a single run (making this technique cost-efficient) with a 
shorter turn-around time than clinical exome sequencing [28–30]. Gene panels have 
been implemented to diagnose mitochondrial disorders [31], epilepsy [32], retinal 
dystrophies [29], inflammatory bowel disease [33], cardiomyopathies [34] as well as 
amplicon-based targeted sequencing of breast cancer [9] and myeloid malignancies 
[35]. In addition to the reliable detection of mutations, such panels are able to detect 
even low-percentage mosaicisms like those seen in tumor materials [28,36]. 
Given that sequencing of the entire human genome has not been a generally 
accessible option until recently, the first real success of WGS was that it became 
possible to accurately detect and measure fetal DNA in maternal serum to screen 
for fetal aneuploidies using a noninvasive method [37–39]. More recently, however, 
with the availability of the newer generation of high-capacity sequencers, together 
with a further reduction in sequencing costs, WGS is being considered more and 
more often as the ultimate option for diagnostic testing. In addition to exomic 
variants, WGS is able to detect pathogenic structural variations like inter- and 
intrachromosomal translocation or chromosomal rearrangements [40–42]. 
With all these exiting possibilities at hand, and further technological 
improvements expected, the biggest challenge in using NGS techniques lies in the 
data-interpretation. For instance, exome sequencing yields approximately between 
20,000 and 50,000 variants per sequenced exome. These figures vary enormously 
among different sequencing studies depending on the ethnicity of the patients [43], 
the method used for exome enrichment, the sequencing platform, sequencing depth, 
and the algorithms used for mapping and variant calling [44]. Identifying causal 
mutation(s) against a huge background of non-pathogenic polymorphisms and 
sequencing errors is a key challenge when interpreting NGS results. For instance, 
each human genome harbors about 100 genuine loss-of-function variants with 
around 20 genes completely inactivated [45]. Thus, having as much complementary 
information as possible, such as the pedigree or population structure, inheritance 
pattern, phenotypic features, known or unknown etiology, knowing whether a 
phenotype arises owing to de novo or inherited variants, linkage and/or homozygosity 
mapping data, is of utmost importance for optimal customized variant interpretation 





Aim of this thesis 
The research presented in this thesis focuses on WES applications for unravelling 
the genetic basis of human hereditary disorders by (i) screening of a comprehensive 
set of known disease-causing genes for mutations; (ii) identifying novel candidate 
disease genes in genetically heterogeneous disorders with different possible 
inheritance patterns; and (iii) developing bioinformatic tools to improve on the 
possibilities for selecting putative candidate genes by in silico analyses.  
A diagram summarizing the structure of this thesis is shown in Figure 2. In 
Chapter 2, I examine the utility of WES as a diagnostic approach for establishing a 
molecular diagnosis in a highly heterogeneous group of patients with microcephaly 
and variable intellectual disability. Many patients with microcephaly and intellectual 
disability have a rather indistinguishable and non-specific phenotype. Diagnostic 
testing through candidate gene testing by Sanger sequencing is rather limited and the 
diagnostic yield is generally low. We therefore set out to apply WES as a tool to 
survey all microcephaly genes reported thus far in a single test and to determine 
WES’s usefulness in diagnosing patients. 
  
 
Figure 2: Structure of this thesis. 
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In Chapter 3 we set out to identify the disease gene in a Dutch family with a 
boy affected by familiar glucocorticoid deficiency (FGD) by applying trio-exome 
sequencing.  
Chapter 4 aims to identify a novel disease causing gene for L1 syndrome, an 
X-linked disorder, by application of a variant of WES. To date, L1 syndrome is 
known to be caused by mutations in the L1CAM gene, but many unsolved cases 
remain after mutation analysis of this gene. Pursuing the hypothesis that the 
disorder is considered to be X-linked, i.e. that the causative gene should be located 
on the X chromosome, we initiated X-exome sequencing in a cohort of male 
patients. 
Chapter 5 describes the development of an in silico composite network to 
predict novel candidate genes that might be involved in congenital microcephaly. 
Unsolved cases are a prevalent problem in diagnostics and researchers are often 
confronted with the limitations of WES to detect pathogenic mutations. Non-
coding variants or inadequate quality of sequence in true causative gene may lead 
investigators to miss causal mutations. In addition, and importantly, undiscovered 
gene(s) associated with a given disorder are clearly a main explanation for unsolved 
cases. In the latter situation, applying in silico methods to create composite biological 
network from publically available database-resources could provide new, additional 
candidate genes to be considered in identifying disease-genes.  
Finally in Chapter 6 I will discuss the effectiveness and limitations of 
applying WES for molecular genetic studies on human disease, as well as  discussing 
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Clinical and genetic heterogeneity in monogenetic disorders represents a major 
diagnostic challenge. Although the presence of particular clinical features may aid in 
identifying a specific cause in some cases, the majority of patients remain 
undiagnosed. Here, we investigated the utility of whole-exome sequencing as a 
diagnostic approach for establishing a molecular diagnosis in a highly heterogeneous 
group of patients with varied intellectual disability and microcephaly. 
Whole-exome sequencing was performed in 38 patients, including three sib-
pairs, in addition to or in parallel with genetic analyses that were performed during 
the diagnostic work-up of the study participants. In ten out of these 35 families 
(29%), we found mutations in genes already known to be related to a disorder in 
which microcephaly is a main feature. Two unrelated patients had mutations in the 
ASPM gene. In seven other patients we found mutations in RAB3GAP1, 
RNASEH2B, KIF11, ERCC8, CASK, DYRK1A and BRCA2. In one of the sib-
pairs, mutations were found in the RTTN gene. Mutations were present in seven out 
of our ten families with an established etiological diagnosis with recessive 
inheritance. 
We demonstrate that whole-exome sequencing is a powerful tool for the 
diagnostic evaluation of patients with highly heterogeneous neurodevelopmental 
disorders such as intellectual disability with microcephaly. Our results confirm that 
autosomal recessive disorders are highly prevalent among patients with 
microcephaly. 




Microcephaly, a disproportionally small head size defined as occipitofrontal 
circumference at or below -3 standard deviations (SD), is an important neurological 
sign usually associated with developmental delays and intellectual disability [1]. 
Microcephaly can be congenital or may develop later after birth. It can occur as a 
more or less isolated finding or as one of the features of a more complex syndrome. 
To date, according to the London Medical Database [2], more than 800 syndromes 
with microcephaly have been described, reflecting an enormous number of possible 
diagnoses. Microcephaly may stem from a wide variety of genetic or non-genetic 
conditions and is considered to be a consequence of abnormal brain development. 
Non-genetic causes include foetal alcohol exposure, perinatal infections, asphyxia or 
haemorrhage. Microcephaly can also occur in patients with inborn errors of 
metabolism, but this explains only a small proportion of the total cases [3]. In the 
majority of patients a genetic cause is suspected [4]. Chromosomal abnormalities 
may account for 15-20% of patients [5]. In a retrospective study of 680 children 
with microcephaly [6], a specific genetic cause was detected in 15.3% of them, with 
numerical chromosome aberrations accounting for 6.8% and 
microdeletions/duplications and monogenetic disorders accounting for the other 
8.5%. Over the last few years the number of genes related to microcephaly has been 
rising, primarily as a result of the increased use of whole-exome sequencing (for an 
overview see [7]). This clinical and genetic heterogeneity represents a major 
diagnostic challenge. Although the presence of additional clinical findings may aid in 
identifying a specific cause in some cases, the majority of patients with microcephaly 
remain undiagnosed. Yet an early and specific diagnosis is important because it can 
provide relevant information about disease prognosis, appropriate medical or 
supportive care, reproductive consequences for parents and other family members, 
and prenatal diagnostic options. It may also preclude unnecessary further, and 
possibly invasive, diagnostic tests and evaluations.  
The diagnostic work-up of microcephaly is extensive and includes brain 
imaging, metabolic and ophthalmologic evaluations, skin or muscle biopsies, 
karyotyping or microarray analysis, and mutation analyses of microcephaly genes. 
However, the use of targeted approaches, such as candidate gene testing by Sanger 
sequencing, is rather limited and their diagnostic yield is generally low. In contrast, 
because whole-exome sequencing does not require a priori knowledge of the gene 
or genes responsible for the disorder under investigation [8], it has been proven to 
be a very effective technique for identifying new genetic causes of microcephaly [9, 
10].  




In this study, we investigated the utility of whole-exome sequencing as a 
diagnostic approach for establishing a molecular diagnosis in a highly heterogeneous 
group of patients with microcephaly and intellectual disability. 
 
Materials and Methods 
Study subjects 
We performed whole-exome sequencing in 38 patients, including three sib-pairs, 
with severe microcephaly and varied intellectual disabilities (Table 1). Patients were 
recruited, both prospectively and retrospectively, from the population of patients 
with intellectual disability referred to the genetics departments of the University 
Medical Centre Groningen and the Academic Medical Centre in Amsterdam. 
Informed consent was obtained from the participating families and the study 
protocol was approved by the Ethics Committee of the University Medial Centre 
Groningen. 
The clinical characteristics of all 38 patients are summarized in Table 1. The 
average age of the patients was 10 years (range 0 to 57 years). The majority (87%) 
were children, with only five patients over 18 years of age. Severe microcephaly was 
defined as an occipital frontal head circumference of at least 3 SDs below the age-
related mean according to Dutch national reference curves. The mean occipital 
frontal head circumference Z-score for our patients was -4.5 SD (range -3 to -8 SD). 
Consanguinity was reported for the parents of six patients (patients# 16, 23, 27, 28, 
29, 35), including one of the three sib-pairs. Phenotype information was retrieved 
from medical records and provided by the referring physicians.  
All patients had undergone genetic testing during their routine diagnostic 
work-up. In addition to whole-exome sequencing, the work-up may have included 
standard chromosome analysis, metabolic screening, or DNA sequencing of 
individual or multiple genes. On average, 2.8 DNA tests (range 0 to 9 tests) were 
performed per family (supplemental Table S1). The most frequently tested gene was 
ASPM. This gene was analysed in seven (20%) of the families.  
 
  


















SNP array analysis was performed in all patients prior to inclusion using the 
IlluminaHumanCytoSNP-12 v2.1 DNA Analysis BeadChip following the 
manufacturer’s instructions (Illumina, San Diego, CA, USA). Normalized intensity 
and allelic ratios were analysed using GenomeStudio Data Analysis Software and the 
cnvPartition v3.1.6 algorithm to assess copy number variation. No causal copy 
number variants were found (data not shown). Homozygosity was determined as 
were, if possible, any shared haplotypes within a family. Shared homozygous 
stretches between the siblings with consanguineous parents were detected by 
selecting regions in which both siblings shared the same homozygous alleles; for the 
sib-pair with a recessive disorder we selected regions in which they shared the same 
combination of alleles, and for the sib-pair with a dominant disorder we selected 
regions in which they shared at least one allele at each SNP position. Stretches of 
homozygosity were detected within a single patient by selecting regions that only 
showed homozygous alleles.  
Whole-exome sequencing 
Library preparation was based on the SureSelect All Exon V4 bait protocol (Agilent 
Technologies, Inc., Santa Clara, CA, USA), and carried out on a PerkinElmer® 
SciClone NGS workstation (PerkinElmer, Inc., Waltham, MA, USA). Briefly, 3 
micrograms of genomic DNA were randomly fragmented with ultrasound using a 
Covaris® instrument (Covaris, Inc., Woburn, MA, USA). Adapters were ligated to 
both ends of the resulting fragments. Fragments with an average insert size of 220 
bp were excised using the LabChip XT® gel system (PerkinElmer) and amplified by 
PCR (98 oC 2 min; 11cycli of 98 oC 30s, 65 oC 30s, 72 oC 1 min; 72 oC 10 min). The 
quality of the product was verified by capillary electrophoresis on the LabChip GX 
instrument (PerkinElmer). Of this product, 500 ng was subsequently hybridized to 
the Agilent SureSelect® All Exon V4 bait pool (Agilent Technologies, Inc.). During 
subsequent enrichment with PCR (98 oC 2 min; 11 cycli of 98 oC 30s, 57 oC 30s, 72 
oC 1 min; 72 oC 10 min), individual samples were bar-coded and the quality of the 
product was again verified on the LabChip GX instrument. The product had an 
average fragment size of 360 bp, and was sequenced using 100 base pair reads 
paired-end on an Illumina® HiSeq2000 in pools of four samples per lane (Illumina). 
Resulting image files were processed including demultiplexing using standard 
Illumina® base calling software.  
All lanes of sequence data were aligned to the human reference genome build 
b37, as released by the 1000 Genomes Project [11], using Burrows-Wheeler Aligner 
[12]. Subsequently the duplicate reads were marked. Using the Genome Analysis 
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Toolkit (GATK) [13], re-alignment around insertions and deletions detected in the 
sequence data and in the 1000 Genomes Project pilot [11] was performed, followed 
by base quality score recalibration. During the full process the quality of the data 
was assessed by performing Picard [14], GATK Coverage and custom scripts. SNP 
and indel discovery was done using GATK Unified Genotyper and Pindel [15], 
respectively, followed by annotation using SnpEff [16]. This production pipeline 
was implemented using the MOLGENIS compute [17] platform for job generation, 
execution and monitoring. For each sample, a vcf file was generated that included all 
variants. Mean target coverage of 64x was achieved, with more than 82% of targeted 
bases having at least 20x coverage (supplemental Table S2). Sample swab was 
excluded by a concordance check with the SNP information from the array. 
DNA interpretation 
For data interpretation we uploaded the vcf files to Cartagenia NGS bench 
(Cartagenia, Leuven, Belgium) and then filtered the variants. We removed variants 
covered by less than five sequence reads and possibly benign variants annotated in 
dbSNP133, the 1000 Genomes project, the Seattle exome database [18], or the 
GoNL database [19] with an allele frequency above 2%. Additionally, variants that 
were annotated in eight control samples, and for which exome sequencing was 
performed in the same sequence run, were also removed because they were 
considered to be artefacts. The remaining variants were filtered on any occurrence in 
known genes related to the phenotype, using a filter with selected phenotype traits 
[HPO-terms for microcephaly (HP:0011451, HP:0005484, HP:0000253), 
abnormalities of the nervous system (HP:0002011, HP:0000707), and abnormality 
of the head (HP:0000234) ][20] in the Cartagenia filter tree. The remaining variants 
were assumed to be related to the phenotype and further filtered on an inheritance 
model. First, an autosomal recessive inheritance model was applied for gene 
identification, then an autosomal dominant or X-linked inheritance model was 
applied. We considered variants resulting in transcriptional or splice site effects as 
potentially pathogenic. For the remaining group of variants, including those without 
a phenotypic match, we checked for their presence in the professional HGMD 
database (Biobase-international, Beverly, MA, USA) and manually checked the 
relationships between variants and possible phenotypes. The effect of potentially 
pathogenic variants was explored in the Alamut prediction program (Alamut, 
Rouen, France) or based on information from available databases and literature. 
 
 




Validation of mutations by Sanger sequencing 
Candidate pathogenic variants were validated by Sanger sequencing. When available, 
we studied segregation of these confirmed variants by investigating DNA samples 
from additional family members. Sequencing analysis was carried out using flanking 
intronic primers (primer sequences are available upon request). The forward primer 
was designed with a PT1 tail (5’-TGTAAAACGACGGCCAGT-3’) and the reverse 
primer with a PT2 tail (5’-CAGGAAACAGCTATGACC-3’). PCR was performed 
in a total volume of 10 µl containing 5 µl AmpliTaq Gold ®Fast PCR Master Mix 
(Applied Biosystems, Foster City, CA, USA), 1.5µl of each primer with a 
concentration of 0.5 pmol/μl (Eurogentec, Serian, Belgium) and 2 µl genomic DNA 
in a concentration of 40 ng/μl. Samples were PCR amplified and sequenced 
according to our standard diagnostic protocols (available upon request).  
 
Causality criteria 
To designate candidate pathogenic variants as causative, variants confirmed by 
Sanger sequencing were required to occur in genes in which mutations are known to 
cause a disorder with clinical features consistent with the patient’s phenotype. All 
variants were either reported in the literature or HGMD database [21] to be 
deleterious, classified as truncating or having a splice site effect, or predicted to be 
deleterious at least in three prediction algorithms in Alamut. The presence of 
candidate pathogenic variants was checked in the 1000 Genomes project, the Seattle 
exome database [18],  Exome Variant Server [22], and Exome Aggregation 
Consortium (ExAC) [23]. Furthermore, when possible, familial segregation was 
investigated to determine whether this was consistent with the expected mode of 
inheritance. Causative variants were then reported to the referring physicians.  
 
Results 
On average 34,580 single-nucleotide variants and small insertions or deletions were 
found in each patient by whole-exome sequencing (see supplemental Table S3). A 
molecular diagnosis could be established in 11 patients from 10 families, 
corresponding to a diagnostic yield of 29%. The inheritance of these mutations were 
autosomal recessive (N=7 families), autosomal dominant (N=2) and X-linked 
(N=1). In three patients, a molecular diagnosis was reached during their diagnostic 
work-up while performing exome sequencing (patient 1, patient 26 and patient 32). 
All three of these diagnoses were also reached by whole-exome sequencing. In the 
remaining 25 families, we identified five possibly candidate genes (data not shown). 
However, for none of these candidates a causal relationship to the phenotype of the 
patients could be proven. 
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Mutations were detected in nine different previously identified microcephaly 
genes: ASPM, RAB3GAP1, RNASEH2B, KIF11, RTTN, ERCC8, CASK, 
DYRK1A and BRCA2 (Table 2). None of these mutations was homo- or 
heterozygous present in the databases of benign variants. One exception was the 
variant in RNASEH2B [c.529G>A]. This mutation has been described before [24] 
and is predicted to be pathogenic by Alamut .It was heterozygous reported in the 
ExAC database with a frequency of 0.13%.  
We identified ASPM mutations related to primary microcephaly type 5 [25] in 
two independent families. Patient 6 had two novel mutations in the ASPM gene: a 
deletion of four base pairs resulting in a frameshift and a splice site mutation.  
Sanger sequencing of the parents confirmed segregation. The other ASPM 
mutations (in patient 32) had already been detected by Sanger sequencing: a stop 
mutation and an insertion of one base pair resulting in a frameshift.  
In two patients with clinically recognizable syndromes (i.e. Warburg Micro 
syndrome and Aicardi-Goutières syndrome), mutations in RAB3GAP1 (patient 1) 
[26] and RNASEH2B (patient 26) [24] related to these conditions were identified 
during their diagnostic work-up as well as by whole-exome sequencing. In 
RAP3GAP1 a homozygous deletion of four base pairs in exon 6 was detected. This 
deletion creates a frameshift starting at codon Thr159. The new reading frame ends 
in a stop codon 18 positions downstream.  
A frame-shift mutation in the KIF11 gene was identified in patient 4, who 
was known to have microcephaly and retinopathy, consistent with the phenotype. 
The mutation is an insertion of one base pair resulting in a frameshift and after eight 
amino acids causing a stop codon. The mutation in this patient proved to be 
inherited from the mother, who also had microcephaly and mild learning problems, 
but who was not found to have any ophthalmologic abnormalities. The unaffected 
maternal aunt of patient 4 did not carry the mutation. 
We found a compound heterozygous frame-shift and missense mutation in 
the RTTN gene encoding the centrosome-associated protein Rotatin in one of the 
three sib-pairs (patients 8 and 9). The missense mutation was predicted as 
deleterious by several programs (including Polyphen, SIFT, and Mutation taster).  
In the ERCC8 gene a homozygous frame-shift mutation was found in patient 
16, located in an 8 Mb homozygous region causing a stop codon further in the exon. 
Sanger sequencing of the parents confirmed that both were carriers of this 
heterozygous mutation.  
We further found a splice-site mutation in the CASK gene in patient 19, and 
analysis of the parents confirmed that this was a de novo mutation. This mutation 
results in a predicted change of the splice site.  




We identified a frame-shift mutation in the DYRK1A gene in patient 23, 
which was not inherited from the patient’s mother. Because DNA of the patient’s 
father was not available for testing, we were unable to confirm a de novo event in our 
patient, but the mutation is highly likely to be pathogenic.  
A homozygous mutation in the BRCA2 gene was detected in patient 24. 
Biallelic BRCA2 mutations cause Fanconi anaemia complementation group D1 [27], 
a phenotype consistent with the phenotype of this patient. Sanger sequencing of the 
parents confirmed segregation. Since both parents of our patient were heterozygous 
for the mutation, and because of the associated increased risk for cancer, both of 
their families were offered appropriate genetic counselling and mutation screening. 














Overall, a molecular diagnosis was established in 29% of the families with 
microcephaly studied using whole-exome sequencing. This diagnostic yield is 
comparable to the diagnostic yield of 25% for whole-genome sequencing reported 
in a study of patients with a wide range of suspected genetic disorders, mostly 
related to neurologic conditions [28]. Our results are also in line with other studies 
on the diagnostic utility of whole-exome sequencing in genetically highly 
heterogeneous disorders. Whole-exome sequencing had a higher diagnostic yield 
than Sanger sequencing in patients with deafness (44% vs. 10%), blindness (52% vs. 
25%), mitochondrial diseases (16% vs. 11%) and movement disorders (20% vs. 5%) 
[29]. In a study of 188 probands from families with consanguineous parents and two 
or more affected children, mutations in known genes were found in 27% of the 
patients [8]. A similar diagnostic yield of approximately 25% was obtained in a study 
on consanguineous families from Qatar [30].  
We found mutations that are highly likely to be causative in nine different 
genes known to be associated with a disorder in which microcephaly is an important 
phenotypic feature. The ASPM gene is related to primary microcephaly type 5, 
which is the most common cause of autosomal recessive inherited primary 
microcephaly [31]. Although ASPM was the most frequently tested gene during the 
diagnostic work-up of the patients (Table S1), in one of these two families this gene 
had not been tested. Mutations in the KIF11 gene are known to cause autosomal 
dominant inherited microcephaly with or without chorioretinopathy, lymphedema, 
or mental retardation [32], a phenotype that is consistent with the clinical features of 
the patient in which we identified a KIF11 mutation. Homozygous missense 
mutations in the RTTN gene have recently been identified in patients with 
microcephaly, intellectual disability, epilepsy and bilateral polymicrogyria [33]. The 
p.H865R mutation identified in our family results in a substitution of an amino acid 
that is located in the second Armadillo-like domain of Rotatin, a protein-protein 
interacting domain that is highly conserved among species. Sanger sequencing in 
both parents and two unaffected siblings confirmed that the mutations segregated 
with the clinical phenotype in this family, further proving causality. In our patients, 
the type of cortical malformations differed and the degree of microcephaly was 
more severe than in these published cases. It is known that such heterogeneity in 
distribution, severity and type of cortical malformations can occur in relation to 
mutations in one specific gene, as has been observed with mutations in the GPR56 
gene [33, 34]. ERCC8 gene mutations cause Cockayne syndrome type A [35]. 
Although, in retrospect, this diagnosis is consistent with the clinical features of our 
patient, it had not been considered prior to our discovery of the ERCC8 gene 
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mutation by whole-exome sequencing. When the patient was re-evaluated, his facial 
features had changed substantially and had become more characteristic of Cockayne 
syndrome. Mutations in the CASK gene cause mental retardation with microcephaly 
and pontocerebellar hypoplasia [36]. This X-linked condition is seen more 
frequently in females than in males [37]. The presence of severe intellectual 
disability, spasticity, seizures, absence of speech, and prominent upper incisors 
reported in our CASK patient are known clinical features associated with this 
disorder [38]. Unfortunately, no brain MRI was available from this patient so it 
remains unknown whether she also had pontine or cerebellar hypoplasia. The 
absence of this information may also explain why this diagnosis had not been 
considered prior to whole-exome sequencing. DYRK1A mutations cause autosomal 
dominant mental retardation type 7, in which microcephaly is an important clinical 
finding [39, 40]. Typically, de novo DYRK1A mutations are found [39] as was most 
likely the case in our patient. Biallelic BRCA2 mutations are known to cause 
Fanconi anaemia type D1 [41], and we found a homozygous mutation in this gene. 
Secondary microcephaly and hepatocellular carcinoma, as seen in our patient, are 
known features of Fanconi anaemia [27]. This particular BRCA2 mutation has been 
identified in families with familial breast cancer [42].  
In our cohort an autosomal recessive disorder was detected in 7/10 of the 
families with an established diagnosis, while only eight out of 35 (23%) families had 
been suspected of having a recessive disorder (six consanguineous families and two 
families with affected siblings). This is consistent with the high empirical recurrence 
risk in sibs (approximately 15-20%) of patients with severe primary microcephaly 
without an identified cause [43]. Our results suggest that autosomal recessive 
inheritance is far more frequent in patients with microcephaly than in patients with 
intellectual disability overall [28, 44]. In a study of 100 patients with severe 
intellectual disability, mostly de novo mutations with an assumed dominant effect 
were identified and only one patient was found to have an autosomal recessive 
disorder [45].  
 Our results confirm the clinical and genetic heterogeneity in patients with 
microcephaly. When whole-exome sequencing is performed early in the diagnostic 
work-up of patients, it may prevent other, unnecessary, diagnostic evaluations. Most 
of the patients in our study had had extensive diagnostic evaluations but these had 
not led to a specific diagnosis in the majority of cases. Neveling et al calculated that 
when three or more genes per patient are investigated by Sanger sequencing, whole-
exome sequencing is more cost effective and has a higher diagnostic yield [29].  
 
 





Our results demonstrate that whole-exome sequencing is a powerful tool for the 
diagnostic evaluation of highly heterogeneous neurodevelopmental disorders. We 
performed whole-exome sequencing in 35 families with intellectual disability and 
microcephaly. A molecular diagnosis could be established in 29% of the studied 
families. In 70% of the families an autosomal recessive condition was present, 
confirming that this inheritance mode is more prevalent among patients with 
intellectual disability who have microcephaly.  
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Supplementary Table S1: Genetic tests performed during the diagnostic work-up 
of the study participants. 
Patient Number of 
tests 
Genetic tests 
1 1 RAB3GAP 
2 1 UBE3A 
3 8 ASPM, NBN, MCPH1, WDR62, CDK5RAP2, CEP152, 
CENJP, STIL 
4 0 - 
5 5 SHH, SIX3, GLI2, ZIC2, TGIF 
6 0 - 
7 7 UBE3A, SNRPN methylation, MECP2, MCT8, mtDNA 
(Mito chip), TUBA1A, WDR62 
8 0 - 
9 
 
7 DCX, LIS1,TUBA1A, FLNA, POMT1, POMGnT1, 
mtDNA (m3243A>G; m8344A>G; m8993T>G/C) 
10  0 - 
11 0 - 
12 1 FMR1 
13 3 MCPH1, ASPM, FMR1 
14 3 ZEB2, FMR1, MCT8 
15 0 - 
16 6 FMR1, MCT8, POLG, TIMM8A, ECGF1(MNGIE), 
mtDNA (Affymetrix resequencing array 2.0) 
17 0 - 
18 1 MECP2 
19 2 MECP2, CDKL5 
20 1 MYCN 
21 1 Leber Congenital Amaurosis chip (Asper version 2010) 
22 7 WDR62, CDK5RAP2, CENPJ, CEP152, STIL, MCPH1, 
ASPM 
23 0 - 
24 3 CDKL5, MECP2, FMR1 
25 7 KCNJ11, ABCC8, GCK, H19/LIT1 methylation, GHR, 
STAT5B, IGF1 
26 9 MECP2, CDKL5, UBE3A, TCF4, FOXG1, RNASEH2A, 
RNASEH2B, RNASEH2C, TREX1 
27 1 GPR56 
28 0 - 
29 0 - 
30 2 ASPM, MCPH1 
31 4 CHD7, KAT6B, MED12, UBE3B 
32 2 ASPM, MCPH1 




Patient Number of 
tests 
Genetic tests 
33 6 HNF1β, PKHD1, NPHP3, Bardet-Biedl syndrome micro-
array (Asper version 5), mtDNA (Mito chip), BCS1L 
34 0 - 
35 4 MCPH1, ASPM, NBS, Fanconi anemia (mitomycine C test) 
36 3 ASPM, STIL, MCPH1 
37 0 - 
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Supplementary Table S2: Specification of the sequence data. 
Samples  Mean Min Max 
Genome size (bp) 3101804739 3101804739 3101804739 
Bait size (bp) 51695938 51374954 51756122 
Target size (bp) 51695938 51374954 51756122 
Total number of reads 119523589 75682208 174102599 
On target bases (Mb)  3306.90 2141.65 4660.77 
Aligned bases (Mb)  8863.88 5714.48 12854.38 
Mean bait coverage  62.51 40.11 87.64 
Mean target coverage 63.97 41.38 90.05 
Fraction bp on bait 0.28 0.20 0.37 
Fraction bp near bait 0.12 0.08 0.22 
Fraction bp off bait  0.38 0.26 0.49 
Fraction bp not aligned 0.11 0.05 0.16 
Capture specificity  0.62 0.51 0.74 
Fraction target covered ≥ 2x 0.96 0.95 0.99 
Fraction target covered≥ 10x  0.90 0.84 0.96 
Fraction target covered ≥ 20x  0.82 0.68 0.88 
Fraction target covered ≥ 30x 0.71 0.52 0.83 
Fraction usable bases on target 0.28 0.20 0.37 
Mean read length  95 95 95 
Strand balance 0.50 0.5 0.5 
Median insert size 224 175 369 
Mean insert size  226.49 172.72 353.71 
Standard deviation insert size  52.22 25.41 99.69 
Number of SNPs for concordance  2635 2103 3311 
Concordance 1 1 1 
Name of the bait set(s) used in the hybrid selection for this project: 
SureSelect All Exon 50MB baits hg19 human g1k v37 
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Familial glucocorticoid deficiency (FGD) is an autosomal recessive disorder 
characterized by low levels of cortisol despite high adrenocorticotropin (ACTH) 
levels, due to the reduced ability of the adrenal cortex to produce cortisol in 
response to stimulation by ACTH. FGD is a heterogeneous disorder for which 
causal mutations have been identified in MC2R, MRAP, MCM4 and TXNRD2. 
Also mutations in STAR and CYP11A1 can sometimes present with a phenotype 
resembling FGD. Recently, it has been indicated that FGD can also be caused by 
mutations in NNT (nicotinamide nucleotide transhydrogenase). 
 We identified a 6.67 Mb homozygous region harboring the NNT gene by 
SNP haplotyping in a 1-year old Dutch boy presenting with FGD, but without 
mutations in MC2R and MRAP. Exome-sequencing revealed a novel homozygous 
mutation (NM_012343.3: c.1259dupG) in NNT that was predicted to be disease-
causing. The mutation is located in exon 9 and creates a frameshift leading to a 
premature stop-codon (p.His421Serfs*4) that is known to result in FGD. Both 
parents were shown to be heterozygous carriers. We reviewed the literature for all 
the reported NNT mutations and their clinical presentation. The median age of 
disease onset in 23 reported patients, including the present patient, was 12 months 
(range 3 days to 39 months). There was no difference in age of disease onset 
between truncating and non-truncating NNT mutations. Based on recent literature, 
we advise to monitor patients with FGD due to NNT mutations for possible 












Familial glucocorticoid deficiency (FGD; MIM 202200) is a rare, autosomal 
recessive disorder characterized by undetectable or low levels of plasma cortisol 
despite high plasma adrenocorticotropin (ACTH) levels. The first symptoms 
generally occur during early infancy. FGD can present as an acute adrenal crisis 
precipitated by an intercurrent illness, or with recurrent hypoglycemia (often 
associated with seizures). Nonspecific additional symptoms might be: lethargy, 
failure to thrive, pallor and delayed developmental milestones. In addition, 
hyperpigmentation due to elevated ACTH levels is often seen. Strikingly, serum 
electrolytes are usually normal because aldosterone production is regulated mainly 
by the renin-angiotensin system. Plasma cortisol levels can range from undetectable 
to low-normal in the presence of high ACTH levels and do not respond to 
exogenous ACTH, demonstrating that patients are specifically resistant to ACTH 
[1].  
FGD is a genetically heterogeneous disorder resulting from known mutations 
in MC2R (Melanocortin 2 receptor; MIM 607397), MRAP (MC2R accessory 
protein; MIM 609196), and MCM4 (Minichromosome maintenance 4; MIM 602638) 
[2,3]. Also mutations in STAR (Steroidogenic acute regulatory protein; MIM 
600617) and CYP11A1 (Cytochrome P450, Family 11, Subfamily A, MIM 613743; 
MIM 118485) can sometimes present with a phenotype resembling FGD [4,5]. It 
has recently been reported that mutations in NNT (nicotinamide nucleotide 
transhydrogenase; MIM 607878) and TXNRD2 (Thioredoxin Reductase 2; MIM 
606448) can also result in FGD [3,6]. While mutations in MC2R, MRAP, STAR, 
and MCM4 account for ~50% of FGD patients, NNT mutations are found in 5-
10% of FGD patients [3,7]. Mutations in TXNRD2, has been reported in only one 
Kashmiri family yet [2]. Mutations in MC2R, MRAP, STAR and NNT have been 
found in patients from different ethnic origins. In contrast, only one private 
mutation for MCM4 has been reported, in patients from an Irish travelling 
community [8,9] who presented with a more complex phenotype, including natural 
killer cell deficiency, a DNA repair disorder, and FGD (MIM 609981).   
 When ACTH resistance is associated with alacrima and achalasia of the 
cardia resulting in dysphagia, this constitutes a separate condition known as triple A 
syndrome (AAAS or Allgrove syndrome, MIM 231550) which is caused by 
mutations in AAAS (MIM 605378).  
The NNT gene is located at chromosome 5p12. It consists of 22 exons and 
codes for a 1086 amino acid protein. NNT is a highly conserved enzyme integrated 
in the inner mitochondrial membrane. It comprises three domains: two 
mitochondrial matrix domains and one transmembrane domain (including 14 α-




helixes) that spans the mitochondrial inner membrane (see Fig. 1). The 
mitochondrial matrix domains 1 and 2 contain the binding sites for NAD/NADH 
and NADP/NADPH, respectively, and protrude from the inner membrane into the 
mitochondrial matrix [10]. NNT utilizes the electrochemical proton gradient across 
the mitochondrial inner membrane to produce high concentrations of NADPH 
from NADH. NADPH is needed by glutathione peroxidase for the detoxification of 
reactive oxygen species (ROS) in mitochondria. Thus, NNT deficiency results in 
decreased NADPH production and impaired ROS detoxification [3,6]. Knockdown 
of NNT in a human adrenocortical cell line results in increased apoptosis and 
lowered glutathione peroxidase function. Lower levels of NNT thus make the 
adrenal cortex more vulnerable to ROS damage caused by defective ROS 
detoxification. 
Here we report on a consanguineous Dutch family in whom a novel 
homozygous mutation in NNT led to FGD. We then summarize the pathogenic 
mutations reported in NNT thus far, their localization within the gene and protein 
domains, and their clinical effect. 
 
Materials and methods 
Clinical report  
Our patient, the son of consanguineous Caucasian parents (his paternal great-
grandmother was a sister of his maternal great-grandfather, see Figure 2A), was born 
in breech presentation, after an uneventful pregnancy, at a gestational age of 39 
weeks. His birth weight was 3104 grams and birth length 48 cm. In the first 
postnatal months, he had feeding difficulties and vomited frequently. From the age 
of 4 months, his skin pigmentation increased. His psychomotor development was 
within the normal range. 
At the age of 12 months, he had a long-lasting seizure and a blood glucose 
level of 1.6 mmol/l.  Physical examination revealed mild plagiocephaly, 
hyperpigmented skin and thin, light blonde hair. He cried with tears, excluding triple 
A syndrome. His height (78 cm; +0.56 SD), weight (9.7 kg; -1 SD) and head 
circumference (47.8 cm; +0.4 SD) were within the normal range. He had dark 
pigmentation of the nipples and external genitalia, a penile length of 5.2 cm (+1.8 
SD) and normal testes (2 ml). 
Blood sampling for biochemical and endocrinological studies was performed 
in the morning and revealed normal sodium and potassium concentrations (Na 139 
mmol/l, K 4.5 mmol/l), normal urine sodium and potassium levels (Na 17 mmol/l, 
N 33 mmol/l; measured in a normal hydration state),  a low cortisol level (5 nmol/l, 





Figure 1: Schematic representation of the NNT protein. Amino acid positions and predicted protein 
domains have been adapted from UniProtKB database (Q13423). Purple circles represent the transit 
peptide. Blue circles represent NADH- and green circles NADPH-binding sites. Red circles indicate 
the amino acids where mutations have been reported. Truncating mutations are shown in red boxes 
and non-truncating mutations in black boxes. 
aPredicted result if exon skipped. 
 
Serum 17-hydroxyprogesterone (0.6 nmol/l, normal 0,5-10 nmol/l) and 
androstenedione concentrations  (0.1 nmol/l, normal < 1 nmol/l) were low-normal, 
while the plasma renin activity was within the normal range (3.9 nmol/l/h , normal 
0.8-4 nmol/l/h). Urinary steroid analysis detected no tetrahydrocortisone and no 
abnormal steroid metabolites. No antibodies against the adrenal cortex could be 
detected and serum very long-chain fatty acids were normal. An abdominal 
ultrasound showed normal adrenal glands for the boy’s age. He was treated with 
hydrocortisone 13-15 mg/m2/day to normalize his serum ACTH concentrations. 
He became more active and had no more signs of hypoglycemia or seizures.  
At the start of this study, the NNT gene was not firmly associated with FGD 
and Sanger sequencing in the proband had failed to identify a pathogenic mutation 
in the MC2R and MRAP genes. Therefore, we performed a SNP analysis to identify 
regions of identity-by-descent, followed by exome sequencing with special attention 
paid to variants in the homozygous regions we had identified. 
 





Genomic DNA was extracted from peripheral blood samples from the patient and 
his parents after informed consent was obtained. SNP array analysis was performed 
using the HumanCytoSNP-12 v2.1 DNA BeadChip (Illumina, San Diego, CA, USA) 
and analyzed using GenomeStudio Data Analysis Software and the cnvPartition 
v3.1.6 algorithm DNA samples were enriched using the SureSelect Human All Exon 
V2 Kit (Agilent Technologies, Inc., Santa Clara, CA, USA) according to the 
manufacturer’s instructions and sequenced on an Illumina HiSeq2000. Alignment to 
the human genome reference (UCSC, hg 19 version, build 37.1) was done using 
SOAP aligner [11]. Duplicated reads were removed and an average coverage of 
71.85 was obtained for the target regions. The Soapsnp software [12] was used to 
assemble the consensus sequence and to call genotypes in target regions and 
flanking regions. For insertions or deletions (indels) in the target regions, reads were 
aligned to the reference genome via the Burrows-Wheeler Aligner [13] and indels 
were identified by Genome Analysis Toolkit [14]. Variants were annotated using a 
BGI internal pipeline (BGI, Shenzhen, China). We excluded synonymous variants or 
those in the 3’-UTR, 5’-UTR, intronic and intergenic regions. Under a recessive 
model, we retained homozygous variants and compound heterozygous variants in 
the patient. Finally, we excluded common variants (minor allele frequency  ≥ 0.5% 
in both the 1000 Genomes Project and ESP6500). The homozygous variant we 
identified in the NNT gene was validated by amplification of the relevant part of 
exon 9 using 5’-GTGAACATAGGGTGATAGAC-3’ and 5’-
TCAGCATAAAGCTGGCATAC-3’ primers and sequencing using standard Sanger 
sequencing protocols. 
 
Review of the literature 
All NNT mutations and their clinical phenotypes reported in the literature up to 
October 12, 2015 were retrieved from PubMed using NNT [Title/Abstract] AND 
mutation [Title/Abstract] as a query. Subsequently, papers were selected describing 
patients with adrenal insufficiency due to NNT mutations. Additionally, the ClinVar 
database (see Web Links) was searched for pathogenic mutations in NNT. Fig. 1 
shows the reported disease-causing mutations in NNT and their localization within 
the protein domains using information adapted from the UniProtKB database 
(Q13423). One of the reported mutations, c.1A>G, was re-analyzed using ORF 
Finder (see Web Links). This program predicted that the mutation affected NNT 
function (supplement figure A). 
As part of our review analysis, the age of disease onset among three groups 




Wallis ANOVA. For the two sib-pairs [15] described in Table 1, their mean age of 
onset was used in this analysis. Truncating mutations were defined as mutations 
causing a premature termination of transcription, i.e nonsense and frameshift 
mutations, while missense mutations were classified as non-truncating. Splice site 




Genome-wide SNP analysis did not reveal any putative disease-associated copy 
number variants in the patient. However, we identified 25.7 Mb (~0.8%) copy-
neutral regions of homozygosity, including a 6.67 Mb region on chromosome 5 
located at 39548842-46228333 bp, between SNP markers rs6870776 and rs7293466 
(GRCh19/hg37), and harboring the NNT gene (Fig. 2B). Subsequent exome-
sequencing revealed a novel homozygous frameshift mutation in NNT 
(NM_012343.3: c.1259dupG). This mutation was then confirmed by Sanger 
sequencing and both parents were found to be heterozygous carriers (Fig. 2C). The 
mutation is located in exon 9 and creates a frameshift starting at codon His421, 
leading to a premature stop-codon (p.His421Serfs*4). This particular mutation has 
not been annotated in dbSNP or mutation databases, including those of the 1000 
Genomes Project, the National Heart, Lung, and Blood Institute (NHLBI) Exome 
Sequencing Project, nor the Genome of the Netherlands (see Web Links). 
 
Review of the literature 
Our literature review yielded 29 NNT disease-causing mutations in 23 patients with 
FGD, including our patient, two reported sib-pairs and one unrelated patient with a 
recurrent mutation, shown to be a founder mutation by Weinberg-Shukron et al. 
2015). Fifteen patients from 14 families had homozygous mutations and eight 
patients from seven families had compound heterozygous mutations (Table 1). 
Remarkably, almost all mutations are unique and there is a preponderance of 
missense mutations: 17 missense, 7 frameshift (or predicted-to-be frameshift), and 5 
nonsense mutations. For one mutation (c.1A>G; first patient in Table 1), a 
substitution at the initial methionine, the exact effect is unknown. Applying ORF 
Finder showed there is no ATG codon upstream of the one used normally in the 
primary NNT transcript, whereas the closest in-frame ATG codon is located down-
stream at position c.394, and if used, would result in in-frame translation 
(supplement figure A). However, if this is the case, the first 131 amino acids of 
NNT, including the signal peptide (amino acids 1-43), will be missed. As this signal 
peptide is necessary for importing NNT into the mitochondrial membrane, its 




absence may result in no functional NNT in mitochondria. Moreover, the first 
translation-initiating methionine in NNT is an evolutionarily conserved amino acid 
among human, chimpanzee, rat, mouse, cow, chicken, frog and tetraodon (Alamut 
Interactive Biosoftware, supplement figure B). Therefore, we categorized the 
c.1A>G mutation as truncating.  
The 29 mutations are scattered over the gene. Figure 1 visualizes their 
location in the NNT protein. Twenty mutations are located in the mitochondrial 
matrix domains (the largest part of the protein), seven in the transmembrane regions 
and two in the transit peptide. None of the 13 mutations in mitochondrial matrix 
domain 1 are located at the NAD binding site, while two out of the five mutations 
in mitochondrial matrix domain 2 are at the NADP binding site.  
The clinical features of all the reported patients, including ours, are 
summarized in Table 1. Information on the size of the adrenal gland was only 
known for three reported patients, all being normal like in our patient. In three of 
the reviewed families the combination of FGD with mineralocorticoid deficiency 
occurred. The sib-pair of a consanguineous Palestinian family has a homozygous 
NNT mutation (c.598 G>A, p.Gly200Ser). The same authors describe a non-related 
patient with an identical homozygous mutation and shared haplotype, indicating a 
founder mutation. Combined mineralocorticoid and glucocorticoid deficiency was 
documented in all three affected individuals [16]. Additionally, combined adrenal 
failure, precocious puberty and testicular adrenal rest tumor was reported in a 
patient with another homozygous NNT mutation (c.1163 G>A, p.Tyr388Ser) [17].  
For 21 patients, belonging to 19 families, the age of disease presentation was 
known (Figure 3). The median age of onset was 12 months in the 19 families with a 
range of 3 days to 39 months in the 21 individual patients. In four out of the 16 
families with isolated glycocorticoid deficiency, hyperpigmentation of the skin was 
reported as the first clinical presentation. The median age of onset in the six families 
with two truncating mutations was 9 months (range 4-18 months, n=7 patients), in 
the four families with one truncating and one non-truncating mutation it was 13.5 
months (range 7-29 months, n=4 patients), and in the nine families with two non-
truncating mutations it was 12 months (range 3 days to 39 months, n=10 patients) 
(figure 3). These differences are not statistically significant (p=0. 5147).  
Not surprisingly, the age of onset was earlier in those patients presenting with 
a combined adrenal insufficiency. However, if we exclude these patients from our 
analysis the differences in age of onset (9, 13.5 and 15.5 months, respectively) was 







Figure 2: (A) Partial pedigree of our proband with FGD, demonstrating his consanguineous parents. 
(B) SNP array data showing a 6.67 Mb region of homozygosity in chromosome 5 at chr5: 39548842-
46228333 bounded by SNP markers rs6870776 and rs7293466 (GRCh19/hg37). (C) Sequence 
chromatograms of part of NNT exon 9 obtained by Sanger sequencing and showing a homozygous 





































































































































































































































































































































































































































































































































































































































































































































We identified a novel frameshift mutation in NNT in a Dutch patient with FGD. 
The patient showed hypoglycemia and hyperpigmentation, similar to what is 
observed in other patients with a NNT mutation (see Table 1) [6]. DNA diagnostics 
for NNT was at that time not available in the Netherlands. However, the mutation 
could easily be identified thanks to the combination of SNP haplotyping and whole 
exome sequencing in this distantly-related family. Especially in clinical phenotypes 
with heterogeneous causes, whole exome sequencing has proven to be a very 
powerful diagnostic approach [18,19]. 
The question is whether based on phenotype a clinical distinction can be 
made between the different causes of FGD. Clinically, cortisol deficiencies caused 
by mutations in MCM4 and AAAS are not pure FGD syndromes. They both have 
additional features: natural killer cell deficiency and short stature in the MCM4-
related syndrome, and alacrima with achalasia in the AAAS-related syndrome. 
Patients with a disease-causing mutation in STAR usually present with lipoid 
congenital adrenal hyperplasia (LCAH, MIM 201701), which is a more severe 
phenotype than FGD. These patients have adrenal and gonadal insufficiency, with 
high ACTH and renin levels, and low cortisol and aldosterone levels. As a 
consequence, a failure of androgenization occurs in patients with a 46,XY karyotype, 
resulting in complete or partial sex reversal. Atypical or mild LCAH may present as 
FGD [4,20]. Similar to nonclassic LCAH, a partial defect in CYP11A1 may also lead 
to misdiagnosis of FGD [5,21]. 
FGD due to MRAP and MC2R mutations is clinically indistinguishable from 
FGD due to NNT mutations, although it has been suggested, but not yet 
confirmed, that obesity may be part of the phenotype in MRAP mutations [22]. 
Obesity was not reported in the patients with NNT or MC2R mutations. 
Chung et al. [23] showed that MRAP-related FGD (n=22) usually has an 
earlier age of onset (median 1 month; range birth – 1.6 years) than FGD due to 
MC2R mutations (n=40, median 2 years, range 1 week – 16 years). In the 21 patients 
with NNT mutations and an available age of onset presented here, the median age 
of onset was 12 months (range 3 days  – 3.25 years), thus falling in-between the 






Type of mutations in NNT-related FGD 
Following the observed 31% residual NNT activity in a Japanese patient due to a 
homozygous non-truncating mutation (c.644 T>C; F215S) we studied the 
relationship between age of disease onset and type of NNT mutations. Since 
truncating mutations are most likely to result in no protein being produced at all, it 
was not surprising that they were located throughout the NNT gene. The NNT 
non-truncating mutations, however, were often located in or near important 
domains that were likely to affect the function of the NNT enzyme (four out of 14 
were near binding sites and four were within the transmembrane domain). However, 
the age of disease onset between  truncating and non-truncating NNT mutations 
was not statistically significant (Figure 3) and it was not possible to determine a 
reliable correlation between the type of NNT mutations and cortisol or ACTH 
levels. Although the observed residual enzyme activity in the Japanese patient who 
carried a homozygous non-truncating mutation may support the idea that non-
truncating mutations delay the age of disease presentation, we cannot extend this 
finding to all non-truncating mutations. A possible explanation for this is that the 
amount of residual NNT activity might be highly dependent of the location of the 
mutation within the protein. The age of disease onset may also depend on additional 
comorbidity, such as the combined mineralocorticoid insufficiency, usually resulting 
in symptoms occurring earlier in life, as illustrated  in Figure 3. The missense 
mutations resulting in mineralocoritocoid deficiency were located in the 
mitochondrial matrix I domain and both resulted in a Serine amino acid. However, a 
similarly located missense mutation resulting in a Serine residue was found in a 
patient without mineralocoritocoid deficiency (age of onset 19 months). 
A limiting factor of our study is the small patient cohort and larger groups of 
patients are needed to investigate whether the type of NNT mutation indeed is 
correlated with age of disease onset. 
 
Phenotypic heterogeneity 
Among the reviewed patients are four patients from three families with two 
different homozygous missense mutations and the combination of 
mineralocorticoid and glucocorticoid deficiency [16-17]. Mineralocorticoid 
deficiency was excluded in our patient (plasma renin and sodium were last checked 
at the age of 6 years)  and not reported in any of the other patients.  




Figure 3: NNT mutations and age of disease presentation. 
Age of onset of disease in patients with (AA) two truncating mutations (●), (AB) one truncating and 
one non-truncating muation (■), and (BB) two non-truncating mutations (▲). The solid symbols 
represent patients with isolated glucocorticoid deficiency, while the open symbols (∆) are patients with 
combined gluco- and mineralocorticoid deficiency. The solid horizontal line represents the median age 
in each group (for sib pairs the mean age was used when calculating the median age of onset). In 
column BB, the dashed line represents the median age when patients with combined adrenal deficiency 
were excluded from the analysis. The difference in age of presentation between groups (AA, AB and 
BB) were not significant according to Kruskal-Wallis test with and without combined 
mineralocorticoid and glucocorticoid deficiency; the p-values were 0.51 and 0.22, respectively. 
 
in any of the other patients (see Table 1). As explained above, we could not identify 
a genetic explanation for this broader adrenal phenotype, e.g. the missense 
mutations were not located at a specific functional domain. The patient reported by 
Hershkovitz also had a testicular adrenal rest tumor in combination with testicular 
enlargement, precocious virilization and skin hyperpigmentation. The symptoms 
regressed after intensification of glucocorticoid treatment. It should be noted that 
chronic elevation of ACTH may result in adrenal rest tumors, which may regress 
when glucocorticoid therapy is intensified. Although this is not specific for FGD, it 
is worth mentioning and has implications for the surveillance of patients with an 
NNT mutation.   
From recent reports it can be concluded that the phenotypic spectrum of 
NNT mutation is not restricted to FGD but may also include combined adrenal 
insufficiency and extra-adrenal manifestations like gonadal adrenal rest tumors. 
Moreover, an association with left ventricular noncompaction (LVNC) was recently 
reported for heterozygous NNT loss of function mutations [24]. The authors 
identified a single allele NNT mutation in two patients presenting with LVNC, 
without adrenal manifestations. They showed that suppression of Nnt in zebrafish 
caused early ventricular malformation and contractility defects. However, cardiac 
problems were not described in the patients listed in Table 1 who had biallelic 




condition and a normal heart contour on an X-ray of the thorax at the age of 5 
years. No cardiac disease has been documented in the families of the reviewed 
patients, however under-reporting is very likely. More clinical studies are needed to 
investigate the prevalence of LVNC in heterozygous carriers of an NNT mutation. 
Altogether, these recent findings in NNT mutation patients expand our 
knowledge of the phenotypic spectrum of NNT mutations and this has implications 
for the surveillance of these patients. They should be closely monitored for 
combined adrenal insufficiency and extra-adrenal manifestations, e.g. precocious 
puberty, adrenal rest tumors, possibly cardiac manifestations and other symptoms 
we still may not be aware of being associated with NNT mutations. The diagnosis of 
FGD due to NNT  mutations is also important for the family, to check newborns at 
an early age, preventing serious illness or death due to an Addisonian crise, or 
preventing cerebral damage due to hypoglycemia and hypotension. 
 
NNT pathomechanism in FGD 
Although NNT is widely expressed in humans – with its expression most readily 
detectable in adrenal, heart, kidney, thyroid and adipose tissues [6] – we do not 
know why NNT mutations apparently only affect adrenocortical cells. Production of 
ROS within mitochondria is one of the major internal triggers for apoptotic cell 
death [25]. Mice carrying Nnt mutations show slightly disorganized zona fasciculata 
with higher levels of apoptosis than wild-type mice [6]. As Yamaguchi et al. 
suggested, the adrenocortical cells of the zona fasciculata that produce a large 
amount of cortisol may be specifically vulnerable to oxidative stress caused by 
impaired redox potential and increased ROS [7]. Weinberg-Shukron et al. were able 
to provide patient-based evidence that NNT mutations indeed increase cellular 
oxidative stress and impair mitochondrial function and morphology [16]. They 
observed that ROS levels were 40% higher in NNT_p.Gly200Ser homozygous 
fibroblasts compared with control fibroblasts. They also found a significant 
reduction in ATP content (25% less than in healthy control). Additionally, in 50% 
of the patients’ cells the mitochondria had a pathological punctate appearance which 
is known to be related to various apoptotic stimuli [26]. It is possible that functional 
compensation by overlapping antioxidant defense mechanisms protects other cell 
types or tissues in patients with NNT mutations [27]. 
 
Conclusion 
We have identified a novel NNT mutation in a Dutch patient with FGD, using SNP 
haplotyping and exome sequencing, an efficient approach in the heterogenous and 




clinically not easily distinguishable group of FGD disorders. We also synthesized 
the, still limited, data on FGD caused by NNT mutations to date and noticed a 
recent broadening of the phenotype. As a consequence, patients who carry NNT 
mutations should be closely monitored for likely extra-adrenal manifestations. We 
showed that the type of mutation is not apparently correlated with age of disease 
onset. However, larger studies are needed to further investigate this.  
 
Web Links 
1000 Genomes Project: http://www.1000genomes.org/ 
ClinVar database: http://www.ncbi.nlm.nih.gov/clinvar/ 
NHLBI Exome Sequencing Project (ESP) Exome Variant Server (ESP6500SI-V2-
SSA137): http://evs.gs.washington.edu/EVS/ 
Uniprot: http://www.uniprot.org/  
ORF Finder: http://www.ncbi.nlm.nih.gov/gorf/gorf.html 
Alamut Interactive Biosoftware: http://www.interactive-biosoftware.com/ 
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Supplement figure A: ORF Finder result for NNT transcript (NM_012343.3). The yellow boxes 
display first ATG start codon and second in-frame potential ATG, respectively. The red boxes 
represent three out-of-frame potential translational start sites which might result in non-functional 




Supplement figure B: Evolutionary conservation of the M1 residue translation-initiating methionine 
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L1 syndrome is an X-linked recessive disease caused by mutations in the L1CAM 
gene. It is characterized by hydrocephalus, aqueduct stenosis, adducted thumbs, 
spastic paraplegia, intellectual disability, agenesis/dysgenesis of the corpus callosum 
and aphasia. Although the causality of L1CAM gene in L1 syndrome is well-
established, and more than 200 different pathogenic L1CAM mutations have been 
linked to this disorder, the number of unsolved cases remains high. Since 95% of all 
L1 syndrome patients (with and without an L1CAM mutation) are males and 
familial cases mostly show an X-linked recessive inheritance, we focused on the X 
chromosome to find new candidate gene(s).  
Accordingly, we performed X-exome sequencing in a cohort of 58 individuals 
who are suspected to have L1 syndrome but do not carry mutations in the L1CAM 
gene.  
We identified mutations in 7 patients implying five genes as possible 
candidates for L1 syndrome: DACH2, TENM1, AMER1, PQBP1 and CXorf38. 
Three previously identified independent mutations in DACH2 imply this gene as 
the most promising novel candidate gene for L1 syndrome. PQBP1 and AMER1 
have already been linked to known diseases whose clinical spectrum overlap L1 
syndrome. Although a single gene can be associated with more than one disease, 
differences in characteristic features in L1 syndrome suggest that a common genetic 
basis for these disorders may be less likely. An initial follow-up analysis of these five 
genes in an additional 24 patients did not reveal extra mutations indicating that, if 
causative, these genes would probably explain only a small proportion of L1 
syndrome patients. 
 Functional studies are necessary to firmly establish the causative association 







L1 syndrome is an X-linked recessive neurological disorder with clinical pleiotropic 
abnormalities. It comprises four clinically distinct but overlapping neurological 
syndromes [1–3]. The first and most severe form is X-linked hydrocephalus, also 
referred to as hydrocephalus, due to stenosis of the aqueduct of Sylvius (HSAS; 
MIM 307000) [4]. In addition to congenital hydrocephalus, several other phenotypic 
features including adducted thumbs, intellectual disability and lower limb spasticity 
have been documented in this syndrome. Neonatal or infant death has been also 
documented for this subtype [3]. The second form is MASA syndrome (MIM 
303350), a milder form of the disease characterized by light to moderate intellectual 
disability, aphasia, shuffling gait and adducted thumbs [5]. Variable phenotypic 
presentation has been reported in this form of disease even for carriers of the same 
mutation in a single family [6]. The other two forms, which occur much less 
frequently, are X-linked complicated hereditary spastic paraplegia type 1 (SPG1; 
MIM 303350) and (X-linked complicated corpus callosum agenesis (X-linked ACC; 
MIM 304100). These complicated forms may also present with mild to moderate 
intellectual disability [4].  
To date, there is only a single gene known to cause L1 syndrome, L1CAM. 
The L1CAM gene is located on the X-chromosome at Xq28 and consists of 29 
exons which encode a protein of 1,257 amino acids, comprising a signal peptide of 
19 amino acids and a functional L1 protein of 1,238 amino acids [4]. This protein, 
the neuronal cell adhesion molecule L1, is a transmembrane glycoprotein, belongs to 
the immunoglobulin superfamily and is essential in the development of the nervous 
system [2].  
Although the causality of L1CAM in L1 syndrome is well-known and more 
than 200 different pathogenic L1CAM mutations have been linked to this disorder 
[4], many unsolved cases remain. Vos et al. (2010) reported a diagnostic yield of 
22.8% [7] from sequencing the coding regions of the L1CAM gene in a cohort of 
320 patients with L1 syndrome,  and causative mutations were identified in 73 
patients.  
We cannot exclude the possibility of more than one gene being involved in 
the development of L1 syndrome in humans. To test this hypothesis we have 
focused on the X chromosome, since 95% of all L1 syndrome patients (with and 
without an L1CAM mutation) are males and familial cases mostly show an X-linked 
recessive inheritance [8]. Additionally, in a cohort of 98 patients with MASA 
syndrome, 94% of patients were males [3]. In the same study, 70 patients (100%) 
with HSAS (a severe form of L1 syndrome) were males. Accordingly, we set out to 
perform an X-exome analysis to allow a detailed analysis of all X-chromosomal 




genes in a cohort of L1 syndrome patients for whom the L1CAM mutation analysis 
was negative. 
 
Materials and Methods 
1. Study subjects 
We selected a cohort of L1 syndrome patients who were referred for L1CAM 
analysis. All patients presented with hydrocephalus and at least one additional 
common phenotypic feature: macrocephaly, adducted thumb and/or agenesis of the 
corpus callosum. The patients are mainly male, but also included a few females 
diagnosed with L1 syndrome. We included these because female L1 syndrome 
patients with mutations in the L1CAM gene have also been reported [9,10]. 
Previous mutation analysis of the coding regions of L1CAM was negative in all 
patients. Initially, 58 patients were subject to X-exome sequencing. Subsequently, an 
additional 24 patients were tested for targeted analysis of the most interesting 
candidates. 
All patients or their parents gave consent for diagnostic testing and 
subsequent use of DNA to improve diagnostic testing procedures. 
 
2. X-exome sequencing 
2.1. X-exome kit design and library preparation 
We designed an X-exome custom Agilent SureSelect Enrichment kit using 
SureDesign (https://earray.chem.agilent.com/suredesign/).  
Library preparation was performed according to manufacturer’s instructions 
(Agilent Technologies, Inc., Santa Clara, CA, USA) and carried out on a BRAVO 
workstation (Agilent Technologies, Inc.). In brief, 3 µg of genomic DNA were 
randomly fragmented with ultrasound using a Covaris® instrument (Covaris, Inc., 
Woburn, MA, USA). Fragments with an average insert size of 250 bp were selected 
using AMPure Xp beads (Beckman Coulter, Inc.). Adapters were ligated to both 
ends of the resulting fragments and amplified by PCR (98o C 2 min; 12 cycles of 
98oC 30s, 65oC 30s, 72oC 1 min; 72oC 10 min). The quality of the product after size 
selection and amplification was verified by capillary electrophoresis on the 
Tapestation 2200 (Agilent Technologies, Inc.). Of this product, 750 ng was 
subsequently hybridized to the SureSelect XT Custom capture library (S0692382, 
Agilent Technologies, Inc.). During subsequent enrichment with PCR (98oC 2 min; 
14 cycles of 98oC 30s, 57oC 30s, 72oC 1 min; 72oC 10 min), individual samples were 
bar-coded and the quality of the product was again verified on the Tapestation 2200 




paired-end sequencing on an Illumina® HiSeq2500. Resulting image files were 
processed including demultiplexing using standard Illumina® base calling software.  
 
2.2. Data processing 
Sequencing data were aligned to the human reference genome build 37 [11], using 
Burrows-Wheeler Aligner [12]. Subsequently duplicate reads were marked. Using the 
Genome Analysis Toolkit (GATK) [13], re-alignment around insertions and 
deletions detected in the sequence data and in the 1000 Genomes Project pilot [11] 
was performed, followed by base quality score recalibration. During the entire 
process, the quality of the data was assessed by performing Picard (see Web Links), 
GATK Coverage and custom scripts. SNP and indel discovery was done using 
GATK Unified Genotyper and Pindel [14], respectively, followed by annotation 
using SnpEff [15]. This production pipeline was implemented using the 
MOLGENIS compute [16] platform for job generation, execution and monitoring. 
For each sample, a vcf file was generated that included all variants.  
 
2.3. Data filtering  
Figure 1 displays a flow diagram of our filtering strategy, and each step described in 
detail below. For data filtering and interpretation, we uploaded the vcf files into 
Cartagenia NGS bench 4.1.2 (Cartagenia, Leuven, Belgium) and a cohort analysis 
was performed. As an in-house control, we used sequencing data from four male 
samples with a completely different phenotype for whom a pathogenic variant in an 
autosomal gene was detected and two healthy males. 
 
2.3.1. Filtering based on in-house control and frequency in our patient cohort  
We filtered out the variants present in in-house controls or ≥5x in our patient 
cohort. With this filtering step sequencing artefacts, i.e. systematic errors caused by 
our procedures and pipelines, are effectively removed. 
 
2.3.2. Filtering based on allele frequencies 
In this step of our filtering strategy we removed common, possibly benign, variants 
annotated in the 1000 Genomes project (see Web Links), ESP6500 (see Web Links), 
ExAC (see Web Links) and db SNP (see Web Links). All variants with allele 
frequencies ≥1% for all ethnicity groups were excluded from further analysis. 
Afterward, the variants were further filtered according to allele frequency in 
European ethnicities. Indeed, the variants with allele frequency > 1% were excluded 
as possibly benign in the European population including the European American 




ethnicity (ESP6500), the non-Finnish European ethnicity (ExAC) and the European 
ethnicity (1000 Genomes phase 1 and GoNL-V4 (see Web Links); [17]). 
 
2.3.3. Filtering based on variant position in genome 
In this step the variants located in exonic regions or ± 5 bps around exon-intron 
boundary were selected for further evaluation. 
 
2.3.4. Filtering based on impact on protein 
Next, the remaining variants were filtered according to predicted loss-of-function 
effects. Frameshift, start-loss, stop-gain, stop-loss and nonsynonymous missense 
mutations were selected for down-stream interpretation. Putative splice site 
mutations detected in the 5 bps exon-flanking intronic regions were also included. 
Nonsynonymous variants were filtered out based on CADD score (see Box 1). The 
CADD score is a relatively new selection tool in variant interpretation pipelines. It is 
becoming more and more evident that genes have different, specific thresholds [18] 
and thus a gene-specific calibration should be carried out to determine the optimal 
threshold per gene. Since such specific threshold values are not (yet) available, we 
decided to consider variant(s) with CADD score ≥ 15 as potentially damaging 
variants. This cut off value has already been applied in other studies [19,20]. It is 
worth noting that we considered all truncating variants regardless of their CADD 
scores. 
 
2.3.5. Variant interpretation and selection of candidate genes 
Using Alamut software (Alamut, Rouen, France), we checked the impact of chosen 
variants on protein and also their localization in protein domains. The effect of 
splice site variants on splicing process was also predicted by Alamut software. 
Predicted deleterious variants were explored for additional clues to provide evidence 
that these variants may be in genes that can be considered as likely candidate genes 
for L1 syndrome. Therefore we prepared a general summary of biological processes 
in which L1CAM is involved (see Box 2). Additionally, the auxiliary information for 
each candidate gene has been summarized in Table 2. 
 
3. Validation of mutations by Sanger sequencing 
Candidate pathogenic variants were validated by Sanger sequencing. Sequencing 
analysis was carried out using primers for all exons in which likely pathogenic 
mutations were identified upon X-exome sequencing (primer sequences are available 
upon request). Forward primers were designed with a PT1 tail (5’-




CAGGAAACAGCTATGACC-3’). PCR was performed in a total volume of 10 µl 
containing 5 µl AmpliTaq Gold ®Fast PCR Master Mix (Applied Biosystems, Foster 
City, CA, USA), 1.5µl of each primer with a concentration of 0.5 pmol/μl 
(Eurogentec, Serian, Belgium) and 2 µl genomic DNA in a concentration of 40 
ng/μl. Samples were PCR amplified and sequenced according to routine protocols. 
 
4. Follow-up Screening of candidate genes  
In this step five candidate genes were analysed in 24 additional patients affected 
with L1 syndrome. 
 
 
Figure 1: Flow diagram of variant selection strategy. 




































Box 1: Glossary 
CADD: Combined Annotation–Dependent Depletion (CADD) scores, a method 
for objectively integrating many diverse annotations into a single measure (C 
score) for each variant. CADD integrates several well-known tools such as 
PolyPhen, SIFT and GERP. 
 
GeneCards: The Human Gene Database is an integrative database that provides 
comprehensive user-friendly information on all annotated and predicted human 
genes. It automatically integrates gene-centric data from >100 web sources, 
including genomic, transcriptomic, proteomic, genetic, clinical and functional 
information. 
 
Mouse Genome Informatics (MGI): MGI is the international database 
resource for the laboratory mouse, providing integrated genetic, genomic and 
biological data to facilitate the study of human health and disease.  
Box 2: An overview of biological processes in which L1CAM is involved 
 
1 Axon outgrowth and pathfinding [46] 
2 Axon fasciculation (bundling) [47] 
3 Axonal survival [48] 
4 Neuronal migration [49] 
5 Adhesion between neurons and between neurons and Schwann cells [50,51] 
6 Regeneration of damaged nerve tissue [52] 
7 Involvement in integrin-mediated cell–cell and cell–matrix interactions [53] 
8 Synapse formation [54] 
9 Involvement in intracellular second messenger systems [2] 






We generated X-exome data including the L1CAM gene for 58 L1 syndrome 
patients. On average 9,825,718 reads per patient were produced. The mean coverage 
per target was 74 reads with > 93% covered more than 20 times. The fraction of 
bases on target was on average 27%. The cohort analysis by Cartagenia NGS bench 
4.1.2 (Cartagenia, Leuven, Belgium) along with 6 in-house controls resulted in 9364 
variants. For L1CAM the coverage was > 20X in 97% of the gene and we did not 
detect mutations that were missed in previous Sanger sequencing analyses [7]. Next, 
stepwise-filtering finally resulted in seven confirmed mutations, including one 
nonsense and six missense mutations in five different genes (CXorf38, TENM1, 
PQBP1, DACH2 and AMER1) (Table 1). One mutation could not be confirmed by 
Sanger sequencing and the variant’s raw data showed that the calling quality was just 
above threshold, and we therefore re-classified this variant as a false-positive. Four 
variants are novel, not previously observed or reported in any database to our 
knowledge, and three have been reported with very low allele frequencies in the 
ExAC database (Table 1). Auxiliary information for each candidate gene has been 
summarized in Table 2. Two genes (PQBP1 and AMER1) have already been 
documented to be associated with diseases that show clinical overlap with L1 
syndrome phenotypic features. Interestingly, we observed nonsynonymous 
mutations in DACH2 in three patients. No additional putative mutations could be 
detected in these five candidate genes when screening 24 additional patients with L1 
syndrome. 
 
Discussion   
This study set out to identify novel causal X-chromosomal genes in a panel of 58 L1 
syndrome patients for whom the L1CAM mutation analysis was negative. Since 
95% of all L1 syndrome patients (with and without an L1CAM mutation) are males, 
and familial cases mostly show an X-linked recessive inheritance, we hypothesized 
that in addition to L1CAM, other X-chromosomal genes are likely to be involved in 
this disorder. Upon X-exome sequencing we identified mutations in five novel 
candidate genes.  
 
  













AMER1 (also known as WTX) 
We identified a missense mutation (c.2689G>A, p.Asp897Asn) in the AMER1 gene 
in one female patient. APC Membrane Recruitment Protein 1, AMER1, is a protein 
with 1135 amino acids. Germline inactivation of the AMER1 gene leads to 
Osteopathia striata with cranial sclerosis (MIM 300647), a rare X-linked dominant 
disorder which exhibits overlapping features with L1 syndrome such as 
macrocephaly, hydrocephalus, speech delay, hypotonia, mild intellectual disability 
and partial agenesis of corpus callosum. AMER1 ablation in early mesenchymal 
progenitors causes aberrant osteoblastogenesis leading to bone overgrowth in 
mouse [22]. It might be an explanation for observed craniofacial dysmorphism 
(frontal and occipital bossing and macrocephaly) in Osteopathia striata with cranial 
sclerosis (OSCS; MIM 300647). Hearing loss is the most common neurological 
manifestation (46%) and overall 20% of patients present defects of the central 
nervous system (ventricular dilatation, abnormal gyration, or agenesis of corpus 
callosum) and developmental delay. Variable phenotypic presentations have been 
reported even within a family [23,24]. Hirschsprung disease and 
Laryngotracheomalacia have been also observed in some patients [25]. Hemizygous 
males are usually more severely affected than heterozygous females. In males, the 
disorder is usually associated with fetal or neonatal lethality [26].  
To date only truncating mutation in WTX are known to cause OCSC [27]. 
Since it is known that different mutations and different inheritance types may result 
in disorders with distinct clinical entities, we cannot exclude that missense mutations 




We identified a missense mutation in PQBP1 (c.91G>C, p.Glu31Gln) located in 
exon 2 and affecting an evolutionary strongly conserved amino acid. PQBP1 
encodes a polyglutamine-binding protein, PQBP1, whose function is not well 
understood but is thought to play a role in mRNA splicing regulation and mRNA 
translation. PQBP1 mediates neural development by regulating mRNA splicing. 
[28,29]. Defects in PQPB1 lead to Renpenning syndrome (MIM 309500), the 
common features of which include variable intellectual disability, microcephaly, 
craniofacial dysmorphism, velar dysfunction, lean body habitus, sparse hair, short 
stature, selective muscular atrophy and genital anomalies [30,31]. Strabismus, 
spasticity and intellectual disability are the clinical manifestations in Renpenning 
syndrome which show overlap with the phenotypic features of L1 syndrome. 




PQBP1 genes, and 75% (64/85) of patients also presented with a lean body habitus 
[31]. The most common mutations in PQBP1 are deletions and duplications of AG 
dinucleotides within an (AG)6 tract in exon 4, which cause frameshift mutations 
[32]. Only one pathogenic missense mutation (NM_005710.2: c.194A>G, 
p.Tyr65Cys) has been reported [33]. This missense mutation maps within a 
functional region of the protein known as the WW domain (tryptophan-tryptophan 
domain) [34]. The WW domain is a domain composed of 38 amino acids, from 
amino acid 46 to 84. The identified missense mutation in our patient, p.Glu31Gln, 
does not belong to this domain. Probably this mutation causes a disorder with an L1 
syndrome phenotype. 
 
DACH2   
Interestingly, we identified three missense mutations in DACH2 (c.1105G>A, 
p.Glu369Lys; c.1580G>A, p.Arg527Gln; c.514C>T, p.Arg172Cys) in three patients 
(two males and one female). To our knowledge the first two mutations are novel 
and have not been documented in literature or databases. The third mutation, 
p.Arg172Cys, has been observed with a very low allele frequency (0.004%) in the 
ExAC database. 
Mutations in DACH2 have been already reported in two brothers [35]. They 
presented a few phenotypic features similar to those seen in L1 syndrome including 
language disorder, intellectual disability and distinct manifestations like difficulty in 
standing and walking, and urinary and fecal incontinence. They also appeared to 
carry mutations in ABCD1 explaining the observed increased plasma levels of very-
long-chain fatty acids. However, the similar phenotypic features for L1 syndrome in 
these patients might also be related to loss of function in DACH2. 
Additionally, it has been predicted that a putative Dach2-knockout 
mouse model may show abnormal axon guidance as was also observed in 
patients with L1 syndrome [36] (see Box 2 and Table 2). Altogether, the 
detection of three mutations in our cohort suggests DACH2 is an interesting 
novel candidate gene for L1 syndrome. The functional effect of the DACH2 
mutation in our one female patient could perhaps be explained by the 
occurrence of non-random X-inactivation, i.e. if the X- chromosome 









TENM1 (also known as ODZ1 or Teneurin-1) 
We identified a missense mutation (c.4211G>A, p.Arg1404Gln) in the TENM1 
gene. The mutation affects a highly evolutionarily conserved amino acid. This gene 
has not yet been associated with human disease. 
Teneurins are a family of transmembrane glycoproteins conserved from 
Caenorhabditis elegans and Drosophila melanogaster to vertebrates [37]. Teneurin domain 
architecture is highly conserved between invertebrates and vertebrates. In 
vertebrates, Teneurins are expressed most prominently in the brain [38]. In the 
developing chick brain, TENM1 is expressed in many parts of brain including the 
retina, optic tectum, olfactory bulb and cerebellum. It is functionally involved in 
neurite outgrowth, axon guidance and synaptic connectivity in animal models 
[38,39]. The TENM1 intracellular domain was found to contain a nuclear 
localization signal that is required for its translocation to the nucleus [37]. Evidence 
of TENM1 proteolytic cleavage and nuclear translocation of the intracellular 
domain has been reported in chick embryo fibroblasts [40]. Additionally, interaction 
of the teneurin-1 intracellular domain with MBD-1, a methyl-CpG-binding protein, 
suggests the signalling and/or transcriptional regulation role for teneurin-1 [38,40]. 
Altogether, the similar biological functions between TENM1 and L1CAM (see Box 
2) implicate it as a potential candidate gene to further studies. 
 
 CXorf38 
A nonsense mutation ( c.937C>T, p.Q313*) in CXorf38 has been observed in one 
patient. The mutation is located in last coding exon and predicts premature 
termination of protein translation 7 amino acids before normal stop codon. Both 
human CXorf38 and its mouse ortholog (1810030O07Rik) escape X-inactivation 
[41,42], therefore the inheritance pattern is expected to be similar to normal 
recessive inheritance in females. There is not much information available about this 
uncharacterized protein, hence, for now, supportive biological evidence is lacking 
which would connect CXorf38 to L1 syndrome. 
 
Conclusion 
Our X-exome analysis revealed possible disease causing mutations in 7 out of 58 L1 
syndrome patients. This finding implicates another five X-chromosomal genes as 
candidate genes for L1 syndrome. We consider DACH2 as most promising novel 
candidate gene for L1 syndrome based on the identification of nonsynonymous 
mutations in three patients from our cohort. Two candidate genes (AMER1 and 




overlaps with that of L1 syndrome. Such overlap could be explained by the notion 
that different mutations in single gene may result in disorders with distinct clinical 
entities [43–45]. A common basis for L1 syndrome and Osteopathia stiata seems 
less likely because the latter is characterized by an X-linked dominant inheritance 
and frequent hearing loss (42% of patients). The high incidence of microcephaly 
(89%) and lean body habitus (75%) in Renpenning syndrome while these features 
have not been reported or are rare in individuals with L1 syndrome may indicate 
that a common basis of Renpenning syndrome and L1 syndrome is less likely. Still, 
there is a clear rationale for a systematic clinical re-evaluation mutation carriers and 
an extensive mutation analysis of these putative candidates (AMER1 and PQBP1) in 
many more patients. Functional studies are essential to firmly confirm pathogenicity 
of these putative candidate genes (DACH2, TENM1 and CXorf38) for L1 
syndrome. However, even if functionally confirmed, our finding indicates that these 
genes will probably not explain a substantial proportion of L1 patients. 
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The molecular pathomechanisms underlying congenital microcephaly (CM) are 
multifactorial while the etiology of this heterogeneous disorder has still not been 
fully addressed. A marked number of CM cases remain genetically unsolved even 
when using the highly advanced Next Generation Sequencing (NGS)-based 
diagnostic technologies. We aimed therefore to identify biological processes 
underlying CM in relation to already well-established CM-causing genes that may 
also suggest candidate genes for CM. We performed a systematic literature review 
that yielded 76 definite protein-coding CM-causing genes. Next, we carried out an 
integrative composite biological network analysis by using various databases. The 
genes were used for functional enrichment analysis against Gene Ontology (GO) 
annotations, and then the enrichment in each biological function group was 
calculated. 
GO annotations highlighted two previously less addressed biological 
functions underlying CM, telomere biology and tRNA metabolic process, with a 
16.75 and 19.17 fold enrichment, respectively, compared to the entire genome. The 
results also confirmed previously known biological processes such as centrosome, 
spindle pole and microtubule-related-processes, DNA damage repair and DNA 
replication involved in CM. Additionally, the 100 top ranked candidate genes related 
to CM were suggested and evaluated using OMIM, MGI and HGMD databases, of 
which 16 candidates represent a relationship with microcephaly. These 16 candidate 
genes support the idea that our network can potentially suggest CM candidate genes. 
The genes that displayed relationship to CM in mouse models (MGI-based features) 
would probably provide prime candidate for gene-discovery research. Among the 
100 candidate genes, 14 important genes for (neuro)developmental functions might 
be of notable interest and useful for gene identification in unsolved cases presenting 
CM. More generally, this research provides an in silico framework to explore 
candidate genes in any rare genetically heterogeneous Mendelian disease and may 







Microcephaly is most commonly defined as an occipitofrontal head circumference 
(OFC) of less than three standard deviations (SD) below the mean for age, sex, and 
ethnicity. In the original document on the nosology of microcephaly by Opitz and 
Holt, a cut-off of two standard deviations was used [1], while Woods and Parker 
have proposed a cut-off of three standard deviations [2]. A special form of 
microcephaly is autosomal recessive primary microcephaly (MCPH). It is 
characterized by an OFC less than -4 SD at birth and intellectual impairment that is 
not related to other neurological findings, although mild seizures may occasionally 
be present. Most MCPH patients have a normal height, weight and appearance, 
normal chromosome analysis and brain scan results [3]. Congenital microcephaly 
(CM) can be a feature of different multiple congenital anomaly syndromes such as 
Nijmegen breakage syndrome, Seckel syndrome, or Warsaw breakage syndrome [4], 
but can also present as an isolated feature in MCPH. To date, 15 MCPH-causing 
genes have been identified [5–8]. 
The pathomechanism of MCPH and CM is highly heterogeneous. Several 
studies have indicated that common molecular pathomechanisms, such as defects in 
centrosome, spindle microtubule organization, DNA damage repair and cell cycle 
checkpoint control may underlie MCPH [4,5,7,9]. Additionally, MFSD2A, which is 
required for omega-3 fatty acid transport in the endothelium of blood-brain barrier 
has been recently reported as MCPH15 [8]. The other two recently identified 
MCPH genes, PHC1 [10] and ZNF335 [11], appear to be involved in “chromatin 
remodeling”, further suggesting this process is involved also in the pathomechanism 
of CM. 
Recent advances in Next Generation Sequencing (NGS)-based strategies have 
accelerated and revolutionized the identification of causal genes in monogenic 
disorders [12] and also for CM. For example, Abou Jamra et al. (2011) identified 
three CM-causing genes by whole exome sequencing (WES) in three 
consanguineous families [13]. Despite these advances, the causal genetic mutations 
remain unidentified in many of patients with CM or MCPH. In a cohort of 35 
families with patients suffering from microcephaly and variable intellectual disability, 
we could not identify the disease-causing gene in 20 families (70%) even when using 
WES [14]. Similar results have been reported by other researchers [15]. Explanations 
for these genetically unsolved cases (see Box 1) include the current limitations of  
NGS or WES techniques [16] and the fact that not all disease-causing genes have yet 
been identified.  
One way to identify novel candidate genes for unsolved cases, is to focus on 
understanding the underlying pathways and the genes that may display biological 




connections with already established CM-causing genes. Composite biological 
network analysis (see Box 1) aims to identify relevant underlying mechanisms and 
also facilitates the discovery of potential novel causal genes. This can be achieved by 
using a systematic strategy that integrates biological information from many 
different publically available biological databases. In a recent study, Novarino et al. 
(2014) demonstrated the feasibility of such in silico approaches by identifying three 
additional candidate disease genes in families with hereditary spastic paraplegias. 
Putative mutations were found to co-segregate with the disease phenotype by 
applying a network analysis of results obtained from WES [17]. Though the etiology 
of CM is not yet fully understood, this approach has not been applied to CM.  
Here, we carried out a systematic review to compile a list of established causal 
genes for CM. Next, we performed an in silico composite biological network study to 
determine which biological processes may underlie CM. A ranked list of candidate 
genes that are likely involved in CM was also generated. Further, the candidate genes 
were investigated to compile supportive evidence for their relation with 
microcephaly using the following databases: Online Mendelian Inheritance in Man 
(OMIM), Mouse Genome Informatics (MGI), Human Gene Mutation Database 
(HGMD) and Database of Essential Genes (DEG; see Web Links). 
 
Method 
We performed a composite biological network analysis, as previously described[18] 
to identify the biological mechanisms underlying CM and to predict candidate genes 
in which mutations may potentially cause CM. We carried out this analysis in three 
distinct phases as described below and depicted in Figure 1. 
 
Phase 1: Selection of congenital microcephaly genes  
We performed a systematic search in PubMed with a query of MeSH terms 
“microcephaly” restricted to subheading “genetics” and an extra filter on “human” 
species. Candidate genes retrieved from the OMIM database where then grouped 
into four classes based on the a priori defined criteria described in supplementary 
Table 1. The first class includes genes which have been clearly mentioned in OMIM 
as definite causes of CM (or microcephaly in neonates). The second class included 
genes that have been reported repeatedly as causing CM (or microcephaly in 
neonates) in the literature, but are not yet specified in OMIM. The third class 
included possible CM genes in which the onset of disease presentation (i.e. 
microcephaly at birth) has not been reported in either OMIM or literature, or was 
reported in only one patient (i.e. a case report) without additional confirmation by 





Box 1:  
 
Chromosome localization: Any process in which a chromosome is transported to, or 
maintained in, a specific location (Gene Ontology Consortium; see Web Links). 
Co-localization: Genes which are co-expressed in the same tissue, or proteins found 
in the same cellular location (GeneMANIA help page; see Web Links). 
Composite biological network: An integrated network derived from multiple 
biological association networks such as a protein-protein network, co-expression 
network, or pathway network. 
Functional enrichment analysis: A method to identify classes of genes that are over-
represented in a large set of genes. For example, GO-based functional enrichment 
analysis showing which biological functions have been enriched in a large set of genes.  
Genetic interaction: A genetic interaction between two genes generally indicates that 
the phenotype of a double mutant differs from what is expected from each individual 
mutant. 
GO term (Gene Ontology term): An ontology of defined terms representing gene 
product properties. The ontology covers three domains: cellular component, molecular 
function and biological process. 
GO annotation biological function group enrichment: 
The enrichment in a group of GO terms, which are involved in a specific biological 
function. The word “group” refers to a number of GO terms which represent similar 
biological functions. Each GO term consist of several genes which may overlap with 
the other GO terms in the same group. It is calculated by compiling GO terms with 
similar function into a group and then extracting unique related genes in a proposed 
network. Performing the same process for the entire genome, group enrichment will 
then be calculated by comparing the number of genes in a proposed network to entire 
genome (see a descriptive example in Figure 2) 
Hypergeometric probability: The probability of k successes in n draws, without 
replacement, from a population of size N that contains exactly K successes, wherein 
each draw is either a success or a failure (see Web Links for explanation with an 
example). 
False Discovery Rate (FDR): One of family wise error rate, i.e. the probability of 
making one or more false discoveries among all the hypotheses when performing 
multiple hypothesis testing. The FDR is the rate that significant features are truly null. 
For example, a false positive rate of 5% means that on average 5% of the truly null 
hypothesis (H0) in the study will be called significant. 
MeSH term: MeSH (Medical Subject Headings) is the controlled vocabulary thesaurus 
used for indexing articles for PubMed. 
Pathway: Two gene products are linked if they participate in the same reaction within 
a pathway. These data are collected from various source databases, such as Reactome 
and BioCyc via PathwayCommons (GeneMANIA help page; see Web Links). 
Telomere maintenance: Telomere maintenance mechanisms contribute to the 
maintenance of proper telomeric length and structure by affecting and monitoring the 
activity of telomeric proteins and the length of telomeric DNA. 
Unsolved case: Refers to patients who are clinically diagnosed but genetically 
remained undetermined. 




CM genes with incomplete penetrance in patients were also included in the third 
class. The fourth class included genes which did not fall into the first three classes, 
for instance if the onset of microcephaly was not at birth but instead in infancy or 
early childhood. The search process was completed on 15 March 2015.  
 
Phase 2: Building a composite biological network 
Phase 2.1: Selection of in-silico functional data 
We utilized a large set of databases contained within the GeneMANIA package 
(Database version 12-08-2014, Homo sapiens) [19] to build a composite biological 
network. This package comprises 542 networks that collectively utilize more than 
172 million gene-gene associations based on the following databases (see Box 1) of 
co-localization, genetic interaction, pathways, physical protein-protein interactions, 
shared protein domain, and co-expression [19]. Additionally, to insure we explored 
co-expressed genes during brain development in the fetus, we input the following 
five human fetal brain expression data from one expression data set obtained from 
six human fetuses between 13-16 weeks of gestation (Gene Expression Omnibus 
database: accession no. GSE38805) [20] and four distinct fetal brain expression data 
sets from 15-21 weeks of gestation extracted from the atlas of developing human 
brain (see Web Links). 
 
Phase 2.2: Gene Ontology (GO) annotation biological function group 
enrichment and hypergeometric probability test 
 Genes from classes 1 and 2 identified in phase 1 (Table 1) were selected as input 
gene to start the analysis (i.e. they are our training gene set) and to build a 
composite biological network (see Box 1) using the default weighting method. As 
the initial query, we selected “zero″ for the number of related genes. Each CM-
causing gene can be involved to one or more Gene Ontology terms (GO terms; 
see Box 1). The training gene set composed of CM-causing genes was then used 
for functional enrichment analysis against GO terms to identify the most relevant 
GO terms for CM genes. As has been previously advised [19,21,22], we applied a 
FDR<0.05 threshold (see Box 1) to select significant GO annotations. These 
significant GO terms were then categorized based on their corresponding 
biological functions. Those GO terms associated with similar biological functions 
were grouped together and hereafter called a ‘biological function group’. For 
example, there were three GO terms which are related to the telomere biology 
group (supplement Dataset 1). Since each CM-causing gene can be linked to 
different GO terms, duplicate or multiple CM genes were linked to more than one 




CM genes and eventually lead to overestimation of enrichment analysis for the 
affected biological group, we removed therefore duplicated genes in each of the 
biological function group. 
To calculate biological function group enrichment (see Box 1), associated 
genes within each biological function group were extracted from the resulting 
network. Further, across the entire genome , the associated-genes corresponding 
to each biological function group were also extracted (see Web Links). Therefore, 
we generated two gene sets for each biological function group: the first set of 
associated-genes originated from our network analysis and the second set of 
genes was extracted from the entire genome (supplementary Dataset 1 and 2). 
For instance, four out of 76 CM genes are associated with telomere biology from 
our network analyses, whereas 65 out of 20,687 genes in entire genome were 
associated with this biological function group [23]. Biological function group 







To show that these enriched biological processes within our network are highly 
unlikely to have occurred by the chance alone, we performed the exact 
hypergeometric probability test as previously applied [24] (see Box 1 and Web 
Links). Population size was set at 20,687, with is the total number of protein coding 
genes [23]. Sample sizes were 76 genes and 176 genes for phase 2.2 and phase 2.3, 
respectively. The details and number of genes associated with each biological group 
within the entire genome, and within the constructed network are presented in the 
supplementary Dataset S1 for Phase 2.2 and supplementary Dataset S2 for Phase 
2.3. The approach to calculate biological function group enrichment and 
hypergeometric probability test is exemplified in more details for the telomere 
biology group enrichment in Figure 2. The estimates of these analyses are presented 
as enrichment score. 
 
Phase 2.3: GO annotation biological function group enrichment and 
identification of candidate genes for CM  
We input the initially identified genes from Phase 1 as the training gene set and 
performed a composite biological network analysis. The algorithm predicted the 
candidate genes that were most likely to share function with the training gene set. 
[ 
Number of genes in each biological function group in our network
Total genes in our network (N=76 in phase 2.2 or 176 in phase 2.3)
 ]
[ 
Number of genes in each biological function group in entire genome
Total genes in entire genome (N=20687)
 ]
  




This led to the prediction of the 100 top-ranked genes which have a functional 
association to at least one of the CM genes of the training set (supplementary Table 
4). To calculate the enrichment of each of the predicted biological function groups, 
we considered the total number of the possible 176 CM associated genes (i.e. 76 
from phase 1 and 100 predicted from phase 2.3) in our network, and the total 
number of genes in the entire genome was set at 20,687 [23] (see also Box 1). 
 
Phase 3: Confirmation of candidate genes proposed by our network  
To obtain insight into whether genes predicted by our network study may indeed be 
related to CM, the 100 top related genes’ functional properties and reported 
relationships to diseases were studied step-wised in OMIM, MGI, HGMD and 
DEG (see Web Links). We should note that  DEG (see Web Links) is a 
continuously updated on-line database which extracts and compiles essential genes 
from different studies [25]. In OMIM the inclusion of “microcephaly” as an 
important feature in the clinical synopsis was considered as supportive evidence. 
When there was no affirmative documentation in OMIM, the phenotype section of 
the MGI database was checked for descriptions of cerebral cortex abnormalities or 
abnormal brain morphology, which may be associated with microcephaly in mouse 
mutants. All candidate genes were further studied in HGMD® professional release 
2015.4 (see Web Links), where we checked the clinical synopsis for details on 
whether patients with pathogenic mutations in these candidate genes are affected by 
diseases that include microcephaly as a manifestation. For a given gene, when we 
found evidence of a relation to CM in OMIM, MGI or HGMD, we considered this 
as affirmative indication for the causal role of the gene in CM (supplementary Table 
4). Scine human orthologs of mouse essential genes are associated with a wide 
spectrum of diseases [26], we also further investigated the candidate genes which are 
embryonic lethal genes in mice models (MGI) in DEG version 13.3 to check their 
essentiality in human. Essential genes are indispensable for the survival of an 
organism and necessary for basic developmental functions. Loss-of-function 
mutations in essential genes cause lethality during embryogenesis or shortly after 
birth [27]. The Cytoscape software [28] was used to visualize the relations between 






Figure 1: Overview of the study set-up and study phases, and their relationships as implemented in the 
present study 
  





Selection of congenital microcephaly genes  
Our systematic PubMed review resulted in 770 articles, in which 397 candidate 
genes were reported as apparently CM-associated genes. We categorized the genes 
identified through our systematic review into four classes (supplementary Table 1). 
Combination of gene sets from class 1 and 2 led to 77 definite CM-causing genes 
(Table 1): 76 protein coding genes and one small nuclear RNA (SnRNA), 
RNU4ATAC. These 76 genes were then used as input query in phase 2 with the 
exclusion of RNU4ATAC because there was no information about this gene in the 
applied databases. 
 
Building a composite biological network, GO term annotation, and group 
enrichment  
Our approach yielded a list of the top 51 significant GO terms (supplementary 
Dataset S1). We excluded six non-specific GO terms: protein C-terminus binding, 
brain development, organelle assembly, in utero embryonic development, organelle 
fission and nuclear division. The remaining 45 GO terms were categorized into nine 
biological function groups that are important in the context of CM, namely (i) 
Centrosome, spindle pole and microtubule related (14 GO terms); (ii) DNA damage 
repair and cell cycle checkpoint (7 GO terms); (iii) Nuclease activity (5 GO terms); 
(iv) Helicase activity (5 GO terms); (v) Telomere biology (3 GO terms); (vi) DNA 
replication (3 GO terms); (vii) DNA metabolic process (3 GO terms); (viii) 
chromosome localization (2 GO terms) and; (ix) DNA conformation change (2 GO 
terms). Additionally, there were three singleton GO terms of (x) tRNA metabolic 
process, (xi) DNA-dependent ATPase activity and (xii) DNA recombination (Table 
2). The enrichment scores of each biological function group and their 
corresponding significance obtained from the exact hypergeometric probability test 
are presented in Table 2. Of highest interest and novelty, were two previously rarely 
addressed biological functions, telomere biology and tRNA metabolic process, with 
16.75-fold (P=9.2×10-5) and 19.17-fold (P=6.07×10-6) enrichment, respectively. 
Furthermore, and as positive validation, previously well-known CM-associated 
biological functions scored highly, these include centrosome, spindle pole, 
microtubule-related functions (13.12-fold enrichment; P=2.61×10-17) and DNA 
damage repair/cell cycle checkpoint-related function (14.23 folds; P=1.13×10-20) 
displayed the highest number of annotated GO terms in our network analysis. 
Notably, helicase activity including unwinding of DNA duplexes resulting in an 
open conformation (18.9-fold; P=6.5×10-06), nuclease activity including cleavage 




folds-; P=1.80×10-05) were significantly enriched in our network (Table 2, and 
supplementary Table 3). Chromosome localization and DNA conformation change 
also displayed 37.12-fold (P=6.80×10-5) and 12.1-fold (P=9.73×10-6) enrichments, 
respectively.  
Repeating functional enrichment analysis against GO terms (Phase 2.3; using 
176 CM-associated genes), yielded a list of 192 top significant GO terms 
(supplementary Dataset S2). Excluding 26 non-specific GO terms (supplementary 
Dataset S2) left 166 GO terms which were categorized into 21 biological function 
groups according to their similarities in related biological function and 10 singleton 
GO terms (Table 2 and supplementary Table 3). As expected, a higher number of 
GO terms and thus biological function groups emerged (supplementary Table 3) 
due the increased number of genes. Comparing the results of phase 2.2 and 2.3, we 
observed all 12 biological function groups in phase 2.2 appeared once more in phase 
2.3 (Table 2).  
Telomere biology showed a significant enrichment score of 17.85-fold at 
P=2.95×10-12 as did tRNA metabolic processes with an enrichment score 9.93-fold 
at P=2.91×10-05 in phase 2.3. Previously well-known CM-associated biological 
functions, such as centrosome, spindle pole, microtubule-related functions (10-fold; 
P=2.15×10-44), DNA damage repair, cell cycle checkpoint-related functions (9.68-
fold; P=1.88×10-47), nuclease activity including cleavage DNA damaged site (7.98; 
P=6.58×10-10), DNA conformation change (11.32; P=1.30×10-10), helicase activity 
including unwinding of DNA duplexes (13.06; P=1.66×10-07), DNA recombination 
(13.23; P=1.25×10-14), and chromosome localization (21.37; P=3.19×10-05) were 
significantly enriched again in phase 2.3. 
In addition to the GO terms identified in phase 2.2, several additional 
biological functions were indicated in phase 2.3 (supplementary Table 3). Of these, 
two top biological functions with many annotated GO terms showed the highest 
statistical significance in relation with CM: i.) Chromosome and sister chromatid 
segregation (23.88-fold; P=1.03×10-28) and ii.) Kinetochore, centromere and 








Table 1: Systematic review of causal genes reported for congenital microcephaly. 








1 AP3B1* Hermansky-Pudlak syndrome 2 Microcephaly at birth 608233  
2 AP4B1* Spastic paraplegia 47 Microcephaly; Onset at 
birth 
614066  
3 AP4E1* Spastic paraplegia 51 Microcephaly; Onset at 
birth  
613744  
4 AP4M1* Spastic paraplegia 50 Microcephaly; Prenatal 
onset  
612936  
5 AP4S1* Spastic paraplegia 52 Microcephaly; Onset at 
birth 
614067  
6 ASNS* Asparagine synthetase deficiency Microcephaly; Onset in 
utero or at birth 
615574  
7 ASPM* Autosomal recessive primary 
microcephaly 5 
Microcephaly; Onset at 
birth  
608716  
8 C2CD3* Orofaciodigital syndrome XIV Microcephaly; Onset in 
utero 
615948  
9 CENPJ* Autosomal recessive primary 
microcephaly 6;Seckel syndrome 4 
Microcephaly; Onset at 
birth  
609279  
10 CEP135* Autosomal recessive primary 
microcephaly 8 





Muscular dystrophy, congenital, 
megaconial type 
Microcephaly at birth 602541  
12 CLP1* Pontocerebellar hypoplasia type 10 Microcephaly; Onset at 
birth 
615803  
13 EPG5* Vici syndrome Microcephaly at birth 242840  
14 ERCC1* Cerebrooculofacioskeletal syndrome 
4 
Microcephaly; Onset at 
birth  
610758  
15 IBA57* Multiple mitochondrial dysfunctions 
syndrome 3 





Growth retardation with deafness 
and mental retardation due 
to IGF1 deficiency 
Microcephaly, onset in 
utero 
608747  
17 IGF1R* Resistance to Insulin-like growth 
factor I 
Microcephaly; Onset in 
utero  
270450  
18 KIAA1279* Goldberg-Shprintzen megacolon 
syndrome 
Microcephaly; Prenatal 
onset   
609460  
19 KIF5C* Cortical dysplasia with other brain 
malformation   





Natural killer cell and glucocorticoid 
deficiency with DNA repair defect 
Microcephaly; growth 




Allan-Herndon-Dudley syndrome Microcephaly at birth 300523  
22 NDE1* Lissencephaly 4 (with microcephaly) Microcephaly; Onset in 
utero  
614019  
23 OCLN* Band-like calcification with simplified 
gyration and polymicrogyria 
Congenital microcephaly  251290  
24 PHGDH* Phosphoglycerate dehydrogenase 
deficiency 
Congenital microcephaly  601815  
25 PLK4* Microcephaly and chorioretinopathy, 
autosomal recessive, 2 
Microcephaly; Onset at 
birth  
616171  
26 PNKP* Microcephaly, seizures, and 
developmental delay 
Microcephaly; Onset 
prenatally or at birth  
613402  
27 POMT1* Muscular dystrophy-
dystroglycanopathy (congenital with 
brain and eye anomalies), type A, 1 
 
Microcephaly; Onset 










    MIM 
ID 
literature 
28 POMT2* Muscular dystrophy-
dystroglycanopathy (congenital with 
brain and eye anomalies), type A, 2 
Microcephaly; Onset 
prenatally or at birth  
613150  
29 PSAT1* Neu-Laxova syndrome 2 Microcephaly; Onset in 
utero  
616038  
30 QARS* Microcephaly, progressive, seizures, 
and cerebral and cerebellar atrophy 
Microcephaly; Onset at 
birth or early infancy   
615760  
31 RARS2* Pontocerebellar hypoplasia, type 6 Microcephaly; Onset at 
birth or in first days  
611523  
32 RBBP8* Jawad syndrome Congenital microcephaly  251255  
33 SLC25A19* Microcephaly, Amish type Microcephaly; Onset at 
birth  
607196  
34 SLC25A22* Epileptic encephalopathy, early 
infantile, 3 
Microcephaly; Onset in 
first hours to days of life  
609304  
35 SSR4* Congenital disorder of glycosylation, 
type Iy 
Microcephaly; Onset at 
birth  
300934  
36 STAMBP* Microcephaly-capillary malformation 
syndrome 
Microcephaly; Onset at 
birth 
614261  
37 TSEN2* Pontocerebellar hypoplasia type 2B Microcephaly; Onset at 
birth  
612389  
38 TSEN54* Pontocerebellar hypoplasia type 2A Microcephaly; Onset at 
birth  
277470  
39 TUBB* Cortical dysplasia, complex, with 
other brain malformations 6 
Microcephaly; Onset at 
birth  
615771  
40 TUBGCP6* Microcephaly and chorioretinopathy, 
autosomal recessive, 1 
Microcephaly; Onset at 
birth  
251270  
41 WDR62* Autosomal recessive primary 
microcephaly 2 
Microcephaly; Onset in 
utero  
604317  
42 ZNF335* Autosomal recessive primary 
microcephaly 10 
Microcephaly; Onset at 
birth  
615095  
43 ZNF592* Spinocerebellar ataxia, autosomal 
recessive 5 
Microcephaly at birth 606937  
44 AMPD2* Pontocerebellar hypoplasia, type 9 Microcephaly at birth 615809  
45 ATR♣ Seckel syndrome 1 Severe microcephaly at 
birth; Prenatal growth 
retardation  
210600  [37,74] 
46 CASC5♣ Autosomal recessive primary 
microcephaly 4 
Congenital microcephaly 604321 [60] 
47 CDK5RAP2♣ Autosomal recessive primary 
microcephaly 3 
Primary microcephaly 604804 [75] 
48 CDK6♣ Autosomal recessive primary 
microcephaly 12 
Primary microcephaly 616080 [76]  
49 CENPE♣ Autosomal recessive primary 
microcephaly 13 
Congenital microcephaly 616051 [56]  
50 CENPF♣ Ciliary dyskinesia, primary, 31 Primary microcephaly 600236 [58] 
51 CEP152♣ Autosomal recessive primary 
microcephaly 9; Seckel syndrome 5 
Primary microcephaly 613529 [77] 
52 CEP63♣ Seckel syndrome 6 Primary microcephaly 614728 [78] 
53 CKAP2L♣ Filippi syndrome Microcephaly at birth  272440 [62] 
54 CLPB♣ 3-methylglutaconic aciduria, type VII, 
with cataracts, neurologic 
involvement and neutropenia 
Congenital microcephaly 616254 [79] 
55 DDX11♣ Warsaw breakage syndrome  Congenital microcephaly  613398 [80,81] 













    MIM 
ID 
literature 
57 DYRK1A♣ Mental retardation, autosomal 
dominant 7 
Primary microcephaly 614104 [83,84] 
58 EFTUD2♣ Mandibulofacial dysostosis, Guion-
Almeida type 
Microcephaly at birth  610536 [85]  




60 IER3IP1♣ Microcephaly, epilepsy, and diabetes 
syndrome 
Primary microcephaly 614231 [88,89] 
61 KAT6A♣ Mental retardation, autosomal 
dominant 32 
Primary microcephaly 601408 [52] 
62 KIF11♣ Microcephaly with or without 
chorioretinopathy, lymphedema, or 
mental retardation 
Congenital microcephaly 152950 [90,91] 
63 KIF14♣ Meckel syndrome 12 Microcephaly; intrauterine 
growth retardation 
616258 [92] 
64 KIF2A♣ Cortical dysplasia, complex, with 
other brain malformations 3 
Congenital microcephaly 615411 [93] 
65 LIG4♣ LIG4 syndrome Congenital microcephaly  606593 [94] 
66 MCPH1♣ Autosomal recessive primary 
microcephaly 1 
Primary microcephaly 251200 [95,96] 
67 NBS1 
(NBN)♣ 




68 NHEJ1♣ Severe combined immunodeficiency 
with microcephaly, growth 
retardation, and sensitivity to ionizing 
radiation 
Microcephaly at birth  611291 [99] 
69 PCNT♣ Microcephalic osteodysplastic 
primordial dwarfism, type II 
Microcephaly at birth  210720 [100] 
70 PHC1♣ Autosomal recessive primary 
microcephaly 11 
Primary microcephaly 615414 [10] 
71 RAD50 Nijmegen breakage syndrome-like 
disorder 




primordial dwarfism, type I 
Microcephaly at birth 210710 [101] 
73 SASS6♣ Autosomal recessive primary 
microcephaly14 
Primary microcephaly 609321 [6] 
74 STIL♣ Autosomal recessive primary 
microcephaly 7 
Primary microcephaly 612703 [102] 
75 TRMT10A♣ Microcephaly, short stature, and 
impaired glucose metabolism 
Primary microcephaly 616033 [53] 
76 XRCC2♣  Microcephaly at birth 600375 [103] 







‡GeneMANIA cannot recognize RNU4ATAC so it was not used as an input gene in initial gene set; 
*emerged from class 1; ♣emerged from class 2. 
 
As Figure 3 shows, CM-causing genes normally exhibit multifunctional roles 
and represent overlapping biological functions. Several CM-causing genes overlap in 
two, three or even more biological functions suggested to be involved in CM. 




telomere biology, the DNA metabolic process, DNA recombination and nuclease 
activity. NBN (NBS1) shows association with eight biological functions. Of interest, 
we observed the category “tRNA metabolic process; the chemical reactions and 
pathways involved in tRNA processes such as aminoacylation, tRNA end turnover” 
as a distinct biological function (Figure 3), and the genes RARS2, TSEN54, TSEN2, 
CLP1 and QARS are categorized in this group. 
 
Evaluation of the validity of network prediction  
According to OMIM, mutations in seven out of 100 top related genes identified in 
phase 2.3 (MRE11A, BUB1B, PRKDC, PARS, TUBG1, ERCC4 and ATRIP) cause 
disorders in which microcephaly is of one the phenotypic features (supplementary 
Table 4). These genes were not detected in our extensive literature review because 
of e.g. incomplete penetrance or onset of microcephaly in infancy and we have 
grouped them in class 3 of our literature review (see supplementary Table 2). 
Inspection of MGI (see Web Links) for the 93 remaining genes revealed that 
mutations in four genes (BMI1, AGTPBP1, DISC1 and KIF3A) also cause 
microcephaly with phenotypic features such as cerebral cortex abnormalities or 
abnormal brain morphology in knockout mice (supplementary Table 4). Twenty two 
out of the remaining 89 genes cause prenatal lethality in mice models according to 
the MGI database (supplementary Table 4). Because these genes may represent 
essential genes in mice [27], we analyzed these 22 in DEG to check whether these 
genes may also be essential genes in humans. This turned out to be the case for 20 
of the 22 embryonic lethal genes apart from IGFBP4 and GTSE1 (supplementary 
Table 4). Additionally, five probable CM candidate genes were identified by 
analyzing HGMD. Defects in TSEN15 [29], TSEN34 [30], KIF23 [31], IGFBP4 [31] 
and KIF4A [32] have already been reported in human disorders in which 
microcephaly is one of the phenotypic features (supplementary Table 4). There is no 
apparent relation between the remaining 64 candidate genes and CM based on 
OMIM, MGI or HGMD other than that these putative candidate genes show 
significant relationships with well-established CM-causing genes within our network 
(supplementary Table 4). Although the majority of these remaining 64 candidate 
genes are not associated with established disorders in the OMIM database, some 
have been related to diseases in human. RAD51D, for instance, has been associated 
with breast-ovarian cancer, PTCH1 with basal cell nevus syndrome and BRCA1 





















































































































































































































































































































































































































































































































































































































































































































Figure 3: In silico composite network analysis highlighting possible biological functions underlying 
congenital microcephaly (phase 2.2). Green nodes indicate CM-causing genes involved in two 
biological functions. Orange nodes indicate CM-causing genes involved in three biological functions. 
Purple nodes indicate CM-causing genes involved in four or more biological functions.  
 
Discussion 
Despite the recent advances in NGS technology, the etiology of CM is still not fully 
understood and the causal genetic mutations remain unidentified in many of patients 
with CM. We aimed to identify biological processes underlying CM which may 
suggest potential candidate genes in which defects may cause CM. In addition to 
well-known biological processes underlying CM, our network analysis identified two 
less addressed biological processes: “telomere biology” and “tRNA metabolic 
process”. The candidate genes were also further evaluated in silico for CM causality. 
Among 100 candidate genes, 12 genes have already reported for microcephaly in 
human (according to OMIM or HGMD) and four genes were also associated with 
brain abnormalities which are expected to cause microcephaly in mice (according to 
MGI). 
 
Novel biological processes that may be relevant in the etiology of CM  
Our network analysis suggested that two previously less addressed biological 
functions of “telomere biology” and “tRNA metabolic process” may be involved in 




were enriched 16.75 times in CM network. Several lines of knowledge support a role 
for telomere biology in the pathomechanism of CM. Among 76 established CM-
causing genes (Table 1), seven  (MCPH1, ATR, RBBP8, NBS1, RAD50, DNA2 and 
ERCC1) are associated with telomere biology. MCPH1 regulates DNA-damage 
response at the telomeres [33], maintains telomere structure and represses human 
telomerase reverse transcriptase [34,35]. Similarly, the ATR gene is involved in 
telomere protection and stability [36]. Patient primary fibroblasts deficient for ATR 
spontaneously accumulated DNA damage at telomeres [37]. Likewise, mutations in 
RBBP8 causes Jawad syndrome (MIM 251255) and CM is one of its phenotypic 
features. In fact, RBBP8 promotes alternative non-homologous end-joining repair at 
uncapped telomeres [38]. Also, mutations in the NBS1 (also called NBN) gene cause 
Nijmegen breakage syndrome (NBS; MIM 251260) which is characterized by 
microcephaly at birth combined with immunodeficiency and predisposition to 
malignancies [39]. NBS1 is part of the MRE11/RAD50/NBS1 complex (MRN 
complex), which is involved in the DNA double-strand break response pathway [40] 
that plays a role in telomere maintenance (see Box 1) and its organization. Both 
RAD50 and NBS1 cause CM [39,41], and, interestingly, mutations in the first part of 
heterotrimeric MRN complex, MRE11, can also cause microcephaly [42]. The MRN 
complex serves as shelterin accessory factors which are implicated in the generation 
of telomere G-overhangs [43], recombination [44] and telomere length control [45]. 
This finding led us to take a closer look at the other shelterin accessory factors listed 
in the study by Diotti and Loayza [46], and we noticed that ERCC1, MCPH1 and 
ATR are also shelterin accessory factors and mutations in these genes lead to CM 
(Table 1). Additionally, mutations in the other shelterin accessory factors (ORC1, 
XPF and RTEL1) cause microcephaly. However, we grouped these genes in class 3 
of our systematic review (supplementary Table 2), as the onset of microcephaly 
caused by these genes is in the infancy period. As part of origin recognition complex 
(ORC), ORC1 has a role in telomere maintenance [47]. Both XPF [48] and RTEL1 
[49] also play a role in telomere maintenance. Furthermore, two GO terms, 
“telomere maintenance” and “telomere organization” which were enriched in our 
network, were associated with DNA2, ERCC1, RAD50 and NBS1. “Nuclear 
chromosome, telomeric region” were also enriched in our analysis, as ERCC1, 
RAD50 and NBS1 categorized into this GO term (supplementary Dataset S1). 
Taken together, our findings further support a possible involvement of telomere 
biology in the pathomechanism of CM.  
The observed 19.17-fold enrichment of tRNA metabolic process in our 
network highlights a possible relationship of this biological process with CM. Our 
network analysis has linked seven (CLP1, QARS, RARS2, TSEN2, TSEN54, 




KAT6A and TRMT10A) out of the 76 CM-causing genes into the tRNA metabolic 
process in which the first five genes represent a separate gene-network cluster 
among the CM-related genes (Figure 3). Except for QARS, these genes cause 
different subtypes of pontocerebellar hypoplasia (Table 1) that are characterized by 
mostly prenatal onset of stunted growth, decay of cerebral structures and CM [50]. 
Mutations in QARS, encoding Glutaminyl-tRNA Synthetase, cause progressive 
microcephaly associated with cerebral-cerebellar atrophy [51]. Additionally, 
mutations in KAT6A [52], a Lysine acetyl-transferase gene, and TRMT10A [53], a 
tRNA modifying enzyme with methyltransferase activity, cause syndromes 
associated with CM. Yet, the mechanism by which neuronal cells are vulnerable to 
defects in tRNA metabolic processes is not well understood. It has been suggested 
that defects in tRNA processing leading to tRNA fragment accumulation, and might 
trigger the development of neurodegeneration [54] and apoptosis of 
neuroprogenitor cells [55]. Although the majority of CM-causing genes exhibit 
overlapping biological functions, the separate cluster of tRNA metabolic process 
may indicate that this process is involved in a distinct pathway underlying CM 
(Figure 3). 
 
Well-known biological processes underlying CM  
Our network analyses identified previously well-known biological functions 
implicated in CM such as defects in centrosome, spindle pole-related, DNA damage 
repair and cell cycle checkpoint-related functions [4,5,7] and chromosome 
localization [56–58] which have been discussed comprehensively elsewhere. “DNA 
conformation change” was enriched 12.10-fold in our CM network, in which a gene 
set of six genes, (CASC5, DDX11, DNA2, KAT6A, NBN, and RAD50) were 
linked to this biological process. Notably, four of these genes exhibit helicase 
activity. Similarly, chromatin remodeling, which changes DNA conformation, has 
been recently linked to CM [7]. Further support was given by the identification of 
ZNF335 and PHC1 as MCPH genes, called MCPH10 and MCPH11, respectively. 
These genes are associated with chromatin remodeling as well [7,11]. Clinically, loss 
of ZNF335 in neuron progenitors disrupts progenitor cell proliferation, leading to a 
severe reduction in forebrain structure [11]. However, the PHC1 pathomechanism 
in MCPH is not yet completely clear. It has been suggested that mutations in PHC1 
modify chromatin conformation and as a consequence, defects in DNA damage 
repair and cell cycle progression may then lead to MCPH [10]. Two extra top 
enriched biological functions, (i) chromosome and sister chromatid segregation and 
(ii) Kinetochore, centromere and condensed chromosome, which were identified in 




62]. Indeed, definite CM-causing genes accompanied by the top 100 candidate genes 
could evoke a number of already known biological functions in a more efficient 
manner than using only the 76 definite CM-causing genes.  
 
Identification of novel candidate genes for CM 
 Network analysis resulted in a gene set of 100 loci that may be involved in CM, out 
of these different groups of genes can be distinguished. 
The first group of genes is comprised of 16 genes with 
experimentally/clinically represented association with microcephaly. According to 
OMIM, mutations in seven genes out of top 100 genes represent diseases in which 
microcephaly has been reported as a phenotypic feature of their clinical synopsis. 
These genes have been categorized in class 3 of our systematic review, and were not 
included in the initial set of 76 CM causing genes. The other set of four genes has 
been confirmed as potentially causal genes for microcephaly in mice models (MGI). 
These are plausible candidates to screen in unsolved cases with microcephaly or for 
investigation of their functional role in neural progenitor cells, as defects in 
progenitor cell proliferation may lead to CM. It is worth mentioning that mutations 
in DISC1 have been reported in Schizophrenia [63,64] and in patients with agenesis 
of corpus callosum, a developmental abnormality of the brain often associated with 
microcephaly as well [65,66]. Additionally, five genes identified in our analyses 
(TSEN15, TSEN34, KIF23, IGFBP4 and KIF4A) were found to be related to 
microcephaly in HGMD. In fact, only one or two pathogenic mutations have been 
found in these five genes. Among them, interestingly, TSEN15 and TSEN34 are 
involved in the tRNA metabolic process.  
The second group includes the remaining 84 candidate genes for which we 
found no relation with microcephaly in OMIM, MGI or HGMD. Although the 
majority of these are not associated with established disorders, a few genes such as 
BRCA1, RAD51D, PTCH1, SERPINA7, AMN, BARD1 and DCLRE1C have 
been reported for complex diseases in which microcephaly has not been recorded as 
one of their related clinical synopses. Therefore, these genes can probably be ruled 
out as potential CM-causing genes. Interestingly, 22 genes that localize 
predominantly in the center of our network (shown in supplementary Figure 1) are 
associated with prenatal lethality in mice and their characteristics were summarized 
in supplementary Table 4. In addition, based on DEG, 14 human orthologs out of 
these 22 mouse lethal genes not only are essential genes in human but there were no 
survived pathogenic mutation recorded for them in HGMD. Human orthologs of 
such essential genes are considered to have important roles in (neuro)development 
and to be more likely associated with disease based on the observed strong cross-




species conservation, phenotypes in other species and lower mutation rates [27,67–
70]. Dickerson et al. (2011) revealed that the human orthologs of mouse essential 
genes are associated with a wide spectrum of diseases affecting diverse tissues [26]. 
It should be noted that null or severe loss-of-function mutations in essential genes 
may indeed contribute to embryonic lethality, while, hypomorphic mutations (partial 
loss-of-function) in the same genes can contribute to less severe abnormalities that 
are recognized as human disease [26]. Furthermore, it has been shown that human 
disease genes which are also lethal in the mouse tend to be inherited in dominant 
pattern of inheritance and cause developmental abnormalities [26]. Putting all this 
evidence together, examining heterozygous or de novo mutations in orthologs of 
these 22 essential genes is a diagnostic option for unsolved CM patients.  
 
Strength and limitation of the study and further applicability  
Our study implemented an in silico framework for a rare heterogeneous Mendelian 
disease. Such an approach is currently common practice in common diseases, but 
our study is among the first to apply this for a Mendelian disease and, in particular, 
in CM. Previous studies usually only discussed a single biological network or just 
limited biological information [17,71,72], whereas we utilized highly diverse 
biological information to build a comprehensive composite biological network. 
Further strengths of our study are the calculation of biological function group 
enrichment and the in silico evaluation of CM candidate genes. The fact that our 
analysis was able to move from genes back to known biological pathomechanisms 
involved in CM, underlines the feasibility of in silico functional network analysis to 
illustrate (novel) biological processes underlying CM.  
Of note is that incompleteness of GO annotations is a limitation in GO-
based studies. For example, despite involvement of ASPM – a well-established 
MCPH-causal gene – in spindle pole orientation and organization [73], ASPM was 
not among the group “centrosome, spindle pole and microtubule related” gene set 
selected by the GO term. In addition, due to lack of information in applied 
databases, it was not possible to input RNU4ATAC as a query gene, even though 
RNU4ATAC is a SnRNA and defects in this gene causes microcephaly at birth.  
 
Conclusion  
This study aimed to provide novel insights to the pathomechanism of CM. By 
performing an in silico systematic analyses, we built a composite biological network 
for CM from which we implied the biological processes of telomere biology and 
tRNA metabolic processes involved in CM. Using this approach, we confirmed 




repair and cell cycle control, and centrosome-, spindle pole- and microtubule-related 
processes. We further compiled a list of 100 biologically plausible candidate genes 
for CM, which was backed by existing information in OMIM, MGI or HGMD from 
both human and mouse models. We propose that a similar approach is applicable to 
other rare Mendelian diseases. 
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Database of Essential Genes (DGE), http://www.essentialgene.org/  
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Supplementary Table 2: The name of genes grouped in class 3 in alphabetic order 
and the reason to exclude  them from analysis. 
 Gene Phenotype  
MIM number 
Reason to exclude Referenc* 
1 ALG1 608540 Microcephaly neonatal and also postnatal [1] 
2 ALG3 601110 Microcephaly at birth is not clear in OMIM; but head 
circumference is normal at birth based on literature 
[2] 
3 ASXL1 605039 3/7 patients with ASXL1 had primary microcephaly 
 
[3] 
4 ATRIP 606605 Microcephaly in one patient without confirmation by 
animal model 
[4] 
5 ATRX 301040 Microcephaly at birth is not clear in OMIM; 75% of 
ATRX mutations show microcephaly 
[5] 
6 B3GALTL 261540 Microcephaly (22% of patients); onset is not clear in 
OMIM 
OMIM 
7 BCAP31 300475 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM 
8 BLM 210900 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM; [6] 
9 BRCA2 600185 Microcephaly at birth has been reported in a few 
patients, but incomplete penetrance 
[7–10] 
10 BRP44L 614741 Microcephaly, progressive only in 1 patient OMIM 
11 BUB1B 257300 Microcephaly onset is not clear in both OMIM and 
literature 
[11] 
12 CASK 300749 Based on OMIM, microcephaly and onset at birth or 
early infancy; but postnatal microcephaly based on 
Seltzer (2014) 
[12] 
13 CDC6 613805 Microcephaly at birth is not clear in OMIM; 
incomplete penetrance 
[13] 
14 CDT1 613804 Microcephaly at birth is not clear in OMIM; 
incomplete penetrance 
[13] 
15 CEP57 614114 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM 
16 CLPP 614129 Microcephaly (in few patients); onset of disease is not 
clear in OMIM 
OMIM 
17 COG4 613489 One patient had onset at age 4 months after normal 
development  
OMIM 
18 COG6 615328 Microcephaly at birth but with incomplete penetrance OMIM 
19 COX7B 300887 Microcephaly (3/4 patients); onset is not clear OMIM 
20 CRIPT 615789 Microcephaly onset is not clear in literature [7] 
21 CTCF 615502 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM 
22 CTSD 610127 Based on Schulz et al.(2013) age of onset is from 




250800 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM 
24 DKC1 305000 Microcephaly at birth is not clear in OMIM and 
microcephaly seen in Hoyeraal–Hreidarsson 
syndrome variant 
OMIM 
25 DLD 246900 Onset usually in the neonatal period; later onset has 
been reported as well. 
OMIM 
26 DNM1L 614388 Based on OMIM, microcephaly and onset in first 





191350 Two diseases, one microcephaly at birth and the 
second without microcephaly 
OMIM 
28 EFEMP2 614437 Microcephaly (rare): onset is not clear OMIM 
29 EHMT1 610253 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM 
30 EIF2AK3 226980 Onset is not clear in OMIM; incomplete penetrance [16] 
31 ERCC2 601675 Microcephaly onset is not clear in both OMIM and OMIM 




 Gene Phenotype  
MIM number 
Reason to exclude Referenc* 
literature 





615272 Microcephaly; onset  in infancy OMIM 
34 ESCO2 609353 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM 
35 FAM20C 259775 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM 
36 FBXL4 615471 Onset at birth or early infancy; microcephaly (in some 
patients) 
OMIM 
37 FRAS1 219000 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM 
38 FREM2 219000 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM 
39 FRMD4A 616305 Congenital microcephaly based on one family; no 
functional study or animal model 
[17] 
40 FTO 612938 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM 
41 G6PC3 612541 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM 
42 GFM1 609060 Mild microcephaly at birth OMIM; [18] 
43 GLI2 610829 Microcephaly at birth is not clear in OMIM; 
incomplete penetrance  
OMIM 
44 GLI2 165230 Two disease: one microcephaly (but unclear onset of 
disease) the other without microcephaly 
OMIM 
45 GMPPB 615320 Three diseases with microcephaly but with different 
age of onset from birth to 4 years 
OMIM 
46 GNPAT 222765 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM; [19] 
47 GNPAT 222765 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM 
48 HCCS 309801 Onset is not clear in OMIM; incomplete penetrance [20] 
49 HDAC8 
 
300269 Two diseases: one microcephaly (but unclear onset of 




118190 Two diseases: one without microcephaly the other 
with microcephaly (onset between birth and 3 months 
of age) 
OMIM 
51 KCNJ2 600681 Three diseases: one microcephaly (unclear onset), one 
without microcephaly 
OMIM 
52 KCNT1 608167 Two diseases: one microcephaly (but unclear onset of 
disease) the other without microcephaly 
OMIM 
53 LARP7 615071 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM 





614340 Microcephaly (in some patients); onset is not clear in 
OMIM 
OMIM 





300294 Three diseases: two without microcephaly, one 
microcephaly at birth  
 
OMIM 





147920 Microcephaly onset is not clear in OMIM; Some 
patients did not present microcephaly 
[23] 







 Gene Phenotype  
MIM number 
Reason to exclude Referenc* 
61 MRE11A 604391 Two unrelated patients with congenital microcephaly 
but normally Ataxia-telangiectasia-like disorder 
exhibit without microcephaly 
[24] 
62 MYCN 164280 Microcephaly at birth is not clear in OMIM; 
microcephaly (79% of cases) 
OMIM 
63 NALCN 615419 Onset at birth or in infancy(OMIM); but brain MRI 
in six patients was normal 
[25] 






122470 Microcephaly onset is not clear in OMIM; some 
patients did not show microcephaly 
[28] 
66 NOLA3 224230 Microcephaly onset is not clear in both OMIM and 
literature 
[29] 
67 NSDHL 300831 Microcephaly onset is not clear in both OMIM and 
literature 
[30] 
68 NSMCE2 NA Two reported patients, one microcephaly at birth and 
for the other OFC at birth was not clear 
[31] 
69 ORC1 224690 Microcephaly onset is not clear in both OMIM and 
literature 
[13] 
70 ORC4 613800 Microcephaly at birth is not clear in OMIM; 
incomplete penetrance 
[13] 
71 ORC6 613803 Microcephaly at birth is not clear in OMIM; 
incomplete penetrance 
[13] 
72 PAK3 300558 Microcephaly onset is not clear in both OMIM and 
literature 
[32] 
73 PARS 616140 Microcephaly (1 patient); onset in the first year of life OMIM 
74 PDHX 245349 Onset at birth or in early childhood(OMIM); 3/26 
patients reviewed presented with microcephaly 
[33] 
75 PEX7 215100 Microcephaly onset is not clear in both OMIM and 
literature 
[34] 
76 PGAP2 614207 Microcephaly  at birth but incomplete penetrance OMIM 
77 PHF6 301900 Microcephaly at birth is not clear in OMIM; 
incomplete penetrance 
[35] 
78 PIGO 614749 Microcephaly onset at birth; incomplete penetrance [36] 
79 PMM2 212065 Onset is not clear and microcephaly (50% of patients) OMIM 
80 POMGNT1 
 
606822 Three diseases: two microcephaly at birth and one  
without microcephaly  
OMIM 
81 POR 201750 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM 
82 PORCN 305600 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM 
83 PQBP1 309500 Microcephaly at birth is not clear in OMIM; 
incomplete penetrance 
[37] 
84 PRKDC 615966 Immunodeficiency 26, with or without neurologic 
abnormalities in OMIM; therefore incomplete 
penetrance 
OMIM 
85 PTDSS1 151050 Microcephaly (in some patients); onset is not clear in 
OMIM 
OMIM 
86 PTF1A 609069 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM 
87 RAD21 614701 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM; [38] 




89 RPS6KA3 303600 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM 
90 RTEL1 615190 Microcephaly onset in early childhood OMIM 
91 RTTN 614833 Microcephaly onset is not clear in both OMIM and 
literature  
[39] 




 Gene Phenotype  
MIM number 
Reason to exclude Referenc* 
92 SALL1 107480 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM 
93 SATB2 612313 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM 
94 SC4MOL 607545 Microcephaly onset is not clear in both OMIM and 
literature 
[40] 
95 SC5DL 607330 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM 
96 SF3B4 154400 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM 
97 SIX3 157170 Microcephaly onset is not clear in both OMIM and 
literature 
[41] 
98 SKI 182212 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM 
99 SLC35A3 615553 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM 
100 SNAP29 609528 Onset in first months of life OMIM 
101 SOX2 206900 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM 
102 SPOCK1 602264 Microcephaly at birth but only in one patient without 
animal model 
[42] 
103 STT3A 615596 Microcephaly; at birth is not clear; one family; no 
animal model 
[43] 
104 STT3B 615597 Microcephaly at birth is not clear; one patient; no 
animal model 
[43] 
105 TBCE 241410 Microcephaly onset is not clear in both OMIM and 
literature; 21 patients with similar mutation and no 
animal model and functional study 
[44] 
106 TFAP2A 113620 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM 
107 THOC6 613680 Microcephaly onset is not clear in both OMIM and 
literature 
[45] 
108 TUBA1A 611603 Microcephaly at birth is not clear in OMIM; three  
patients with normal neonate parameter 
[46] 
109 TUBA8 613180 Microcephaly at birth but incomplete penetrance OMIM 
110 TUBB2B 610031 Microcephaly onset is not clear in both OMIM and 
literature; Incomplete penetrance 
[47] 
111 TUBB3 614039 Microcephaly at birth but incomplete penetrance OMIM 
112 TUBG1 615412 Microcephaly at birth is not clear in OMIM; 
incomplete penetrance [48] 
OMIM 
113 UBE3B 244450 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM 
114 UBR1 243800 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM 
115 VIPAR 613404 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM; [49] 
116 VPS33B 208085 Microcephaly onset is not clear in both OMIM and 
literature 
OMIM; [50] 
117 ZBTB18 612337 Onset is not clear in OMIM; incomplete penetrance; 
one patient 
OMIM 
118 ZEB2 235730 Microcephaly at birth is not clear in OMIM; 
incomplete penetrance 
[51] 







Supplementary Table 3: Additional biological functions which are likely to be 
involved in CM. These biological functions resulted from phase 2.3, analysis of 176 
genes including 76 definite CM genes along with 100 predicted genes. These 
functions did not emerge from previous phase 2.2, which analyzed only 76 definite 
CM genes. 
#Number of GO terms with FDR<0.05 in each group. 
*Biological function group enrichment calculated according to formula in material method, phase 2.  
‡Hypergeometric probability of drawing exactly number of successes in each biological function group 




Based on 76 definite congenital microcephaly 
genes along with 100 predicted genes 
Number of 
observed 





1 Chromosome and sister chromatid 
segregation 
5 (2.6%) 23.88 1.03×10-28 
2 Kinetochore, centromere and 
condensed chromosome 
9 (4.6%) 14.82 7.77×10-25 
3 DNA ligation 1 (0.5%) 58.77 1.02×10-08 
4 Ubiquitin ligase complex 1 (0.5%) 19.06 6.27×10-07 
5 Viral latency 2 (1%) 42.74 1.58×10-06 
6 Response to ionizing radiation and 
stress 
3 (1.5%) 3.79 2.18×10-06 
7 Midbody 1 (0.5%) 10.16 5.42×10-06 
8 Meiosis 4 (2%) 9.46 8.66×10-06 
9 Regulation of chromosome 
organization 
2 (1%) 9.14 1.08×10-05 
10 Antigen processing and presentation 7 (3.6%) 5.44 1.43×10-05 
11 Regulation of ligase activity 2 (1%) 8.23 2.13×10-05 
12 Aging 2 (1%) 10.37 2.28×10-05 
13 Establishment or maintenance of cell 
polarity 
1 (0.5%) 9.40 3.96×10-05 
14 Fibroblast proliferation 1 (0.5%) 18.08 6.30×10-05 
15 Inositol lipid-mediated signaling 2 (1%) 5.44 1.02×10-04 
16 Protein serine/threonine kinase 
activity 
1 (0.5%) 4.05 1.57×10-04 
17 Insulin receptor 1 (0.5%) 27.12 1.59×10-04 
18 Activation of signaling protein 
activity involved in unfolded protein 
response 
1 (0.5%) 9.04 2.11×10-04 
19 Protein autophosphorylation 2 (1%) 5.52 2.49×10-04 
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The advent of next-generation sequencing (NGS) has revolutionized genomic 
research/diagnostics. NGS provides unprecedented means to carry out the most 
comprehensive genomic analyses. Indeed, the massive capacity of NGS has led to a 
paradigm shift from gene by gene analyses to whole genome analysis. As a result, 
the number of phenotypes with a demonstrated molecular basis in the Online 
Mendelian Inheritance in Man (OMIM) database has more than doubled from 2,048 
in January 2007 [1] to 4,515 in 31th July 2015, mostly as a direct result of the rapid 
adaptation of researchers to using whole exome sequencing (WES) in their gene-
hunting studies. Consequently, WES is now also being rapidly implemented for 
routine diagnostic testing. Clearly, for genetically highly heterogeneous disorders like 
deafness, blindness, mitochondrial disease and movement disorders [2], WES results 
in a significantly higher diagnostic yield than Sanger sequencing.  
This thesis focused on application of WES-based techniques as a molecular 
tool to diagnose/discover pathogenic variants in monogenic disorders. In the course 
of my studies, I have applied current state-of-the-art technological approaches by 
using WES in order to establish a concrete genetic diagnosis for unsolved patients. 
These unsolved cases had already been evaluated extensively by series of diagnostic 
tests including karyotyping, FISH, array-CGH and conventional Sanger sequencing, 
yet the causal mutations remained to be identified. By solving these cases, I have 
shown that these NGS applications can be applied to identify pathogenic mutations 
in genetically heterogeneous diseases (chapter 2 and 3) and to identify novel disease 
genes (chapter 4).  
Despite these promising WES results in diagnostic and research settings [1,3], 
unsolved cases still remain. In chapter 2 we achieved a diagnostic yield of 29% in 
individuals who presented microcephaly with severe intellectual disability. The 
outcome seems promising in this phenotypically and genetically heterogeneous 
cohort. Our yield falls within a range previously reported for neurologic disorders 
(Table 1). The variations in diagnostic yield can be probably attributed to, among 
other causes, differences in disease characteristics and analytical differences with 
respect to exome capturing and filtering strategies and in sample size. 
The high number of unresolved cases points to the importance of potential 




One of the known shortcomings of WES is coverage, which is the number 
of unique reads that overlap a specific genomic region. While an average coverage of 




Table 1: Diagnostic yield of WES in neurologic disorders 
Disease Number 
of patients 








Cohort in which 
approximately 80% 
were children with 
neurologic 
phenotypes 
250 130X 25% [5] 




78 NA 41% [7] 
Severe intellectual 
disability 
100 trios Median coverage 64X, 87% of 




intellectual disability  
(study of de novo 
variants) 
51 trios NA 45-55%‡ [9] 
Moderate or severe 
intellectual disability  
(study of de novo 
variants) 
41 trios Median coverage 135X, 95% of 









35 kindreds 64X 
Range(41X-90X) 
29% Current study 
(chapter 2) 
* WES with focus on 75 known genes 
‡ Because of the extensive locus heterogeneity, final conclusions about the pathogenicity of each individual 
mutation cannot be made. 
NA, not available 
 
Current WES protocols generally capture no more than approximately 80-90% of 
the exons, even at an average coverage of 90X. Hence, this incompleteness of WES 
is a potential source for missed diagnoses [13]. Even assuming 99% of the targeted 
regions are covered above 10X, it means that 0.3 Mb (0.01 x 30 Mb) or 200 genes 
(0.01 x 20,000 genes) will lack sufficient coverage to enable sensitive variant 
detection. From a technical perspective, one the factors contributing to the coverage 
is the GC content. GC is a limiting factor for efficient hybridization and 
amplification during target enrichment [14]. Existing high or low GC contents in a 
genomic region lead, in general, to a less efficient capture probe hybridization [15], 
which ultimately results in low coverage [16,17]. A systematic comparison of exon-
intron structure and GC content for all known genes in the human genome revealed 
that first introns and exons are more GC-rich than last and internal ones [18]. This 
highlights the importance of paying particular attention to the sequencing quality of 





such problematic exons, at least in known genes for a given disorder. In a study of 
genomic sequences of seven ataxia genes targeted on a 2-Mb sequence-capture 
array, for example, two exons (63.6% GC content for exon 1 of the FXN gene; 
76.1% GC content for exon 2 of the SACS gene) showed no coverage at all [19]. An 
improvement in coverage for such problematic gene regions in current WES panels 
would therefore help to fully capture the exome, and this seems feasible as there are 
only small numbers of problematic exons. If we could obtain better coverage in 
WES, it would most likely further improve our diagnostic yield and ultimately solve 
at least some of the currently unsolved cases.  
A second source of uncertainty is that WES does not allow extensive analysis 
of non-coding regions. Non-coding regions of the genome such as introns, 
miRNAs, lncRNAs, snRNA, promoters, enhancers and UTRs are not captured and 
sequenced when using WES. This may be of particular relevance for neurological 
diseases. There is increasing evidence for associations between non-coding RNAs 
and brain development in mice [20–22] or even neurodegenerative and 
neuropsychiatric disorders in humans. Indeed, the association of miRNAs with 
Alzheimer’s [23], schizophrenia and autism [24,25] has been documented. Many 
miRNAs [20] and lncRNAs [26] are highly expressed in the nervous system, and 
miRNAs have been implicated in synaptic plasticity [24], neurogenesis and 
regulating cerebral cortex size [25,27], neural precursor self-renewal and 
differentiation [28] and maintaining the neural progenitor pool [29]. Functional 
studies in mouse models have confirmed these findings. Blocking miR-7 function in 
mouse model, for example, caused microcephaly-like brain defects [30]. As I noted 
in chapter 5, at least two CM-causing genes, MCPH1 and DYRK1A, are regulated 
by miRNAs [31,32]. Likewise, lncRNAs are involved in epigenetic regulation, 
synaptic and neural network connectivity and plasticity, differentiation of neural 
stem cells and progenitors and brain development [33–35]; There are several reports 
on the involvement of lncRNAs in neurodevelopmental disorders such as Prader–
Willi syndrome, Angelmann syndrome, micropthalmia syndrome 3, spinocerebellar 
ataxia 8 and Rett syndrome [34]. The high proportion of identified miRNAs and 
lncRNAs in the brain [36] and their roles in brain functions and developmental 
processes, along with WES-based undiagnosed cases (Table 1), highlight the 
importance of these molecules, at least in neurologic disorders. These observations 
support the idea that a closer look into the non-coding RNAs may lead to the 
discovery of more pathogenic mutations. This notion is supported by the finding 
that defects in snRNA RNU4ATAC lead to congenital microcephaly [37,38]. 
Accordingly it would be an attractive option to extend current WES-based studies 




neurologic disorders because mRNA and non-coding RNA profiles are tissue, time 
and anatomical brain-region-specific [26,39,40], and extracting non-coding RNAs 
from other tissues such as blood or fibroblasts may not provide useful expression 
information. Nonetheless, the potential role of non-coding RNA or cis-regulatory 
elements in Mendelian disease is intriguing, posing a clear challenge that needs to be 
further addressed. 
The third source of uncertainty, which is of lower impact, is the inability of 
WES to detect pseudo-exons. These are exonic-like sequences that are present 
within intronic regions. Insertion of a pseudo-exon may introduce an extraneous 
exon within the mature mRNA that may cause either the disruption of or the 
insertion of a novel stretch of amino acid in the translational reading frame. As a 
result, the normal biological properties of the resulting protein could be disrupted 
[41]. Although pseudo-exons are rarely recognized as a cause of human disease, they 
have been reported in various cancers [41]. Interestingly, as mentioned in chapter 3, 
a previous study of two siblings with familiar glucocorticoid deficiency proved a 
pseudo-exon insertion as cause of the disease [42]. As another example, deep 
intronic sequencing in the STAMBP gene in congenital microcephaly patients 
(chapter 5) found a casual role for a homozygous intronic mutation 
(c.1005+358A>G), which leads to the splicing of a 108bp pseudo-exon containing a 
premature stop codon [43]. While growing evidence indicates that pseudo-exon 
events could explain some of the unsolved cases, these pseudo-exons are generally 
not covered by exome-seq. Therefore, deep resequencing in intronic regions for the 
identification of pseudo-exon insertions may improve current detection of gene-
mutations in unsolved cases. However, in order to be able at all to interpret variants 
identified in the intronic regions, additional cDNA sequencing will be required to 
correctly interpret and define pseudo-exon insertions because there are no effective 
tools as of yet to predict such alterations based solely on the intron-variant 
information.  
 
Challenges in interpretation of variants 
Next to the technical limitations, current interpretations of WES results are also far 
from perfect, and this further contributes to the high number of unsolved cases. 
Translating the results obtained from WES is complicated and relies heavily on our 
current state of knowledge about disease-causing genes and application of a series of 
software-prediction tools to assess the possible pathogenicity of variants. Here, 
there is already an apparent clear lack of knowledge about the potential effects of 
synonymous mutations in disease. Synonymous mutations represent a significant 





proportion of variants detected by WES; it is estimated that 6-8% of single 
nucleotide changes in oncogenes are synonymous [44], and this raises the question 
of whether these mutations may lead to disease. Despite the general concept that 
synonymous mutations do not change the amino acid composition, and are 
therefore less relevant for disease pathology, a number of studies have shown that 
synonymous mutations may cause the disease. Associations with synonymous 
mutations have been reported for at least 50 diseases [45]; of which three have been 
proposed to represent CM-causing genes (NBS1, ERCC1 and IGF1R, see chapter 
5). While the mechanisms by which synonymous substitutions may cause disease are 
not fully understood, particular synonymous mutations may affect splicing accuracy, 
translation fidelity, protein folding, mRNA stability, mRNA secondary structure and 
expression level [46–48]. Among these mechanisms, defects in splicing accuracy 
have been reported more frequently in association with synonymous mutations in 
the literature [45]. We, however, evaluated splicing effects of synonymous mutations 
using in silico analyses throughout this study, but found none of them to be predicted 
as a possible splicing effect variant. Accordingly, the potential impact of 
synonymous mutations remains to be investigated by future in vitro techniques such 
as quantitative RT-PCR, circular dichroism spectroscopy, Western blot and 
ribosome profiling along with in silico analyses [46]. Taken together, this affirms that 
the possible impact of synonymous mutations should not be neglected in WES 
variant interpretation.  
A second challenge is the interpretation of variants located in pseudogenes. 
Pseudogenes are dysfunctional copies of genes that have lost their functional 
expression due to i.) mutations in, or integration into, silent regions of the genome 
and ii.) their ability to encode functional protein because of the presence of 
frameshifts or premature stop codons [49]. Many pseudogenes are transcribed into 
RNA, with some exhibiting a tissue-specific pattern of activation. Pseudogene 
transcripts can be processed into short interfering RNAs that regulate coding genes 
through the RNAi pathway. It has been shown that pseudogenes are capable of 
regulating tumour suppressors and oncogenes by acting as microRNA decoys and 
are able to inhibit/alter the mRNA level of their parent gene [50]. For example, 
PTEN is a tumour suppressor that is often mutated at one allele at cancer 
presentation. The severity and susceptibility to cancer is influenced by the dosage of 
PTEN [51]. A gene-pseudogene pair (here, PTEN-PTENP1) was shown to be co-
regulated by the same miRNA [52]. The miRNA can bind to 3’-UTR of both PTEN 
and PTENP1 where they show 95% similarity in sequence. PTENP1 pseudogene 
acts as a ‘‘miRNA decoy’’, binding to and thereby reducing the effective cellular 




repression. A similar relationship was also demonstrated between the oncogene 
KRAS and its pseudogene KRASP1 [52]. Dramatic changes in the expression of 
pseudogenes were seen during the transition from pluripotent stem cells to early 
differentiating neurons [53]. Indeed, this study identified 1371 pseudogenes that 
were up- or down-regulated significantly during this transition. The number of 
pseudogenes with significant changes in expression during neural differentiation 
may highlight the role of pseudogenes in brain development. It is possible that the 
exact molecular pathomechanism underlying PTEN-PTENP1 or KRAS-KRASP1 
occurs similarly in the genes involved in brain development to down-regulate them. 
Despite these indications for the pathogenicity of pseudogenes in human disease, 
variants in pseudogenes are not always considered in WES analysis. Currently, most 
efforts are directed at distinguishing mutations that occur in the active gene-copy 
from mutations that occur in the pseudo-gene copies, and, in the latter case, these 
are then disregarded as potential disease-causing variants. This may turn out to be 
erroneous in some cases and lead to missing of disease-causing mutations in WES 
experiments. Therefore, variants in pseudogenes deserve more careful consideration 
during the interpretation of WES results to avoid missing pathogenic variants. 
A final limitation in interpreting WES results is our current knowledge of 
established disease-genes. For many disorders there will be yet undiscovered 
causal genes. As previously discussed, unresolved cases are a widespread 
observation in WES studies and; in addition to the issues already mentioned, the 
most significant factor causing this discrepancy may be that our filtering strategies 
are focused on and limited to known disease-genes and -pathways. I strongly believe 
that alternative approaches, such as biological network analysis, will provide novel 
clues and candidate genes for follow-up. In an interesting example, Novarino et al. 
(2014) demonstrated the potential of such alternative approaches by identifying 
three additional candidate disease genes in families with hereditary spastic 
paraplegias by applying a network analysis after WES. In these genes, putative 
mutations were detected that co-segregated with the disease-phenotype [54]. This 
alternative approach highlights the importance of understanding molecular 
pathomechanisms, biological functions and interaction network(s) of established 
disease genes to resolve unsolved cases. Here, bioinformatics tools are a means to 
combine results from the different domains of genetics and genomics, to pinpoint 
and prioritize the potential causal genes for a disease of interest and to augment our 
knowledge about the underlying disease mechanism. To further illustrate the added 
value of such approaches, in chapter 5, I made a first attempt at extending our 
capacity to identify potential CM-related genes by using a composite biological 
network analysis. Starting from 76 established CM-causing genes, as expected, our 





network analysis identified previously well-known biological functions implicated in 
CM such as defects in the centrosome, spindle pole-related functions, DNA damage 
repair and cell cycle checkpoint control. Additionally, our network analysis identified 
another two biological processes, (i.) telomere biology and (ii.) tRNA metabolic 
processes, both of which are probably important pathomechanisms underlying CM. 
Moreover, our analysis identified a further 100 potential candidate genes for 
congenital microcephaly. In silico biological networks are also able to display possible 
biological connections between candidate genes and established disease genes. In 
our research on L1 syndrome, in silico biological network analysis enabled us to 
provide supportive evidence for DACH2 being a novel candidate gene for L1 
syndrome (chapter 4). DACH2 showed biological relationship with L1CAM, the 
only gene currently known to cause L1 syndrome. This biological relationship has 
been mediated via the LAMC1 gene by two edges (Figure 1). Similar to L1CAM, 
LAMC1 is involved in the same pathway (axon guidance).In addition, there is also a 
genetic interaction between DACH2 and LAMC1. Genetic interaction implies that 
these two genes share a functional relationship [55] and may be involved in the same 
biological process or pathway, or they may also be involved in compensatory 
pathways with unrelated apparent functions [55]. A genetic interaction between two 
genes generally indicates that the phenotype of a double mutant differs from what is 
expected from each individual mutant. Further support for such a relation may be 
provided by the fact that mutations in LAMC1 cause Dandy–Walker malformation 
[56], a disease characterized by some overlapping phenotypic features with L1 
syndrome such as hydrocephalus, corpus callosum agenesis and skull defects [57,58]. 
Altogether, our in silico network study highlights DACH2 as a promising candidate 
gene for L1 syndrome. 
In summary, composite biological network analysis provides a valuable in silico 
framework to identify putative candidate genes for any rare, genetically 
heterogeneous Mendelian disease and may facilitate mechanistic understanding of 
the disease. For our CM-research, future studies should concentrate on the 
investigation of both these proposed genes in unsolved CM-kindreds and using 
novel suggested biological processes such as studying the role of candidate genes 
























NGS technologies create exiting new opportunities to study human disease both to 
gain much better insight into the underlying mechanisms  and to improve clinical 
care. In a relatively short time, NGS technologies have found their way into research 
and diagnostics. Gene panel sequencing and WES have become routine in clinical 
applications, particularly for the diagnosis of monogenic disorders. However, as 
discussed in previous sections, the utilization of WES in the diagnostic setting is still 
suboptimal, and currently has some limitations. Further development is needed to 
fully utilize NGS capacities and improve NGS-based diagnostic yield. 
Because of current routine application of WES (coding region), I believe that 
the majority of disease-causing genes will be identified soon. Afterward, the 
remained unsolved cases will lead to a new milestone in human genomic disease in 
future, which I named “Non-codingomics”. In particular, for 
neurologic/neurodevelopmental disorders, the abundance of non-coding RNA in 
the brain and the relatively large number of unsolved cases (Table 1) emphasize that 
special consideration urgently needs to be given to interpreting variants in non-
coding RNAs. To enable the inclusion of non-coding regions, it is expected that 
whole genome sequencing (WGS) will soon replace WES [59,60]. This will provide 
unprecedented opportunities to study possible disease-causing variations outside the 
exome and to call all structural variants, and will probably lead to a significant 
reduction in test costs and turnaround time [61]. 
Figure 1: Biological relationship between a 
candidate gene for L1 syndrome (DACH2) and 
L1CAM. This biological relationship has been 
mediated via LAMC1 by two edges (pathway 
and genetic interaction), i.e. both L1CAM and 
LAMC1 are involved in same pathway (axon 
guidance; as has been experimentally proven and 
reported in Pathwaycommons database). The 
gene-gene interaction between DACH2 and 
LAMC1 has also been experimentally proven 
[71]. This network was generated by the 
GeneMANIA algorithm, which uses existing 
knowledge to visualize the biological 
relationships among genes. 
Light blue lines represent pathways. Dark blue 
lines indicate co-localization. Red lines reflect 
protein-protein interaction. Light brown lines 
show shared protein domains. Green lines 
display genetic interactions.  





To further improve the NGS-based diagnostic yield, we will need other layers 
of information to use as a type of functional read-out for genomic variations. 
Combining genome sequencing with RNA-seq may provide the first of such layers, 
although it will also pose new challenges with respect to obtaining and interpreting 
reliable and relevant expression data. Subsequent integration of these outcomes with 
other omics such as proteomics and metabolomics could provide further layers to 
help in deciphering genomic variants which would enable us to study associations 
of, e.g., post-translational modification, epigenetic alterations or metabolite 
compounds with gene expression and disease causality.  
Obviously, shifting from WES to WGS and adding extra layers of 
information will improve diagnostic possibilities. However, in parallel, there is also 
an urgent need for novel bioinformatics tools to better interpret variants on top of 
what we are able to do now. For example, the ability to predict functional effects of 
variants in non-coding RNA or of intronic variants leading to possible pseudo-exon 
insertions would provide a further improvement of current variant interpretation. In 
the interpretation of variants in coding regions many un-resolved areas still exist 
and, when extending toward the entire genome, many more question marks will 
appear on the horizon.  
Thanks to NGS technologies, the acceleration in identifying novel causal 
genes will gradually help to minimize the “diagnostic odyssey” for patients. Hopes 
are high, especially for complex disorders such as intellectual disability (ID) with 
developmental delay [62,63]. Despite the extensive genetic heterogeneity of ID, 
WGS is now expected to identify the major causes of severe ID in patients for 
whom the diagnostic result upon microarray-based CNV and WES appeared 
inconclusive [64]. Increasing our knowledge of the aetiology of ID by shifting from 
WES to WGS will pave the way for personalized medicine for this clinically and 
genetically heterogeneous disorder. Personalized medicine refers to customization of 
healthcare in which NGS technologies can provide a comprehensive genome-wide 
view of the genetic variations in patients. This may be instrumental for designing 
better individual treatment, more effective diagnostics, personalized risk-prediction 
and tailored therapies. Examples already have been reported: early intervention 
combined with targeted treatment in children with fragile X syndrome improved 
their behaviour and cognition [65], and enzyme replacement therapy when coupled 
with stem cell therapy improved treatment for Hurler syndrome [66].  
In the next few years, WGS will become part of the standard repertoire of 
techniques to guide the treatment of cancer patients [67] and genetic disorders such 
as inherited ocular diseases [68], autism [69] and genetic epilepsies [70]. Accordingly, 




medicine, but, before getting there, we still need to address many challenges, 
including technical limitations, interpretation of variants and better exchanges of 
information between the clinical and genomics disciplines to optimally expand and 
integrate our knowledge. 
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The unprecedented increase in the throughput of DNA sequencing driven by Next-
Generation Sequencing technologies (NGS) now allows for the cost-efficient 
analysis of the entire genome or selected parts of the genome (exome or gene 
panels) for multiple samples in a single sequencing run with a short turn-around 
time. With all these possibilities at hand, the limitations of this technique, such as 
incomplete capturing of all exons and the complexity of variant interpretation, still 
pose major challenges for application of Whole Exome Sequencing (WES) in the 
clinic. The research presented in this thesis focuses on using WES to unravel the 
genetic basis of human hereditary disorders by (i) screening of a comprehensive set 
of known disease-causing genes for mutations; (ii) identifying novel candidate 
disease genes in genetically heterogeneous disorders with different possible 
inheritance patterns; and (iii) developing bioinformatic tools to improve our capacity 
to select putative candidate genes by in silico analyses.  
In chapter 1 we provided background information on NGS-based techniques 
and presented a simplified overview of the main phases in NGS. This chapter 
introduced whole genome sequencing, WES and disease-specific gene panels and 
their applications. The potential of using WES in genome analyses to identify causal 
mutations in diseases with extreme locus heterogeneity is briefly described along 
with the challenges presented by the data-interpretation necessary to identify causal 
mutations(s) against the huge background of non-pathogenic variants. 
In chapter 2 we set out to apply WES as a diagnostic approach for 
establishing a molecular diagnosis in a highly heterogeneous group of patients with 
microcephaly and varied intellectual disability. We achieved a diagnostic yield of 
29% (10 out of 35 kindreds) and found mutations in known disease-genes. Our 
results were in line with other studies on the diagnostic utility of WES in genetically 
highly heterogeneous disorders. Our results confirmed that many microcephaly 
cases are explained by autosomal recessive inheritance (7 out of 10 families). We 
concluded that WES is a powerful tool for the diagnostic evaluation of patients with 
highly heterogeneous neurodevelopmental disorders. 
In chapter 3 we set out to identify the disease gene in a Dutch family with a 
boy affected by familial glucocorticoid deficiency (FGD) by applying trio-exome 
sequencing. Exome-sequencing revealed a novel homozygous mutation 
(NM_012343.3: c.1259dupG) in NNT that was predicted to be disease-causing. The 
mutation is located in exon 9 and creates a frameshift leading to a premature stop-
codon (p.His421Serfs*4) that is known to result in FGD. We also reviewed the 
literature for all reported NNT mutations and their clinical presentation. The 
median age of disease onset was 12 months (range 3 days-39 months). There was no 




NNT mutations. Based on recent literature, we advise that patients with FGD 
resulting from NNT mutations be monitored for possible combined 
mineralocorticoid insufficiency and extra-adrenal manifestations. 
In chapter 4 we aimed to identify novel disease causing genes for L1 
syndrome, an X-linked disorder, by application of a variant of WES. L1 syndrome is 
known to be caused by mutations in the L1CAM gene, but many unsolved cases 
remain even after mutation analysis of this gene. Since 95% of all L1 syndrome 
patients (with and without a L1CAM mutation) are male, and familial cases mostly 
show an X-linked recessive inheritance, we focused on the X chromosome and 
performed customized X-exome sequencing in a cohort of 58 patients in whom the 
L1CAM mutation analysis was negative. We identified mutations in 7 patients 
implicating 5 genes as possible novel candidates for L1 syndrome: DACH2, 
TENM1, AMER1, PQBP1 and CXorf38. Three independent mutations in DACH2 
suggest this gene as the most promising candidate gene for L1 syndrome. Two of 
the remaining candidate genes (PQBP1 and AMER1) had already been linked to 
known diseases whose clinical spectrum overlap L1 syndrome. While a single gene 
can be associated with more than one disease, differences in typical phenotypes in 
L1 syndrome suggest that these disorders may be less likely to have a common 
genetic basis. In a first attempt to identify further mutation carriers, we next 
performed targeted screening of an additional 24 patients for these five candidate 
genes but could not identify an extra variant. In the end, functional studies will be 
essential to firmly establish the causative role of DACH2, TENM1 and CXorf38 in 
L1 syndrome. The number of putative pathogenic mutations in our cohort indicates 
that, if causative, the identified genes can only explain a small proportion of L1 
patients. 
In chapter 5 we aimed to identify molecular pathomechanisms underlying 
congenital microcephaly (CM) and predicted additional candidate CM-causing genes 
based on their relations with well-established causative genes. A systematic literature 
review identified 76 definite CM-causing genes. We then carried out an in silico 
composite biological network analysis on the basis of these genes by integration of 
data from many different publically available biological databases. Our analysis 
highlighted known biological processes (i.e. centrosome and mitotic microtubule 
spindle, DNA damage repair and DNA replication) involved in congenital 
microcephaly. Additionally, it suggested two biological functions, telomere biology 
and tRNA metabolic process, that were previously less addressed in the literature. 
We also ranked the 100 top genes found to be related to any of the initial well-
established CM-causing genes. Evaluation of these proposed candidate genes 
showed that defects in 7 out of the 100 top related genes are already known to be 
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involved in disorders which present microcephaly as one of their phenotypic 
features. Additionally, studying the 93 remaining genes in the Mouse Genome 
Informatics database revealed that mutations in 4 of these genes also cause cerebral 
cortex abnormalities or abnormal brain morphology in knockout mice that are 
expected to result in microcephaly. Subsequent consultation of the Human Gene 
Mutation Database found 5 additional genes associated with microcephaly as a 
phenotypic feature. Altogether, our network strategy provides an interesting 16 
candidate genes that we considered to be important in follow-up studies of unsolved 
cases exhibiting CM. This result also demonstrates the potential of such a network 
approach to facilitate gene discovery in this genetically heterogeneous disease. The 
genes that displayed a relationship to CM in mouse models (MGI-based features) 
and the 14 genes important for (neuro)developmental functions in both mouse and 
human might be of particular interest and prime candidates for gene-discovery 
research. Likewise, similar use of this in silico framework tool would enable 
identification of novel candidate genes for any rare genetically heterogeneous 
Mendelian disease and may facilitate a more detailed mechanistic understanding of 
the disease. 
However, despite the promising results of WES in both diagnostics and 
research settings, unsolved cases remain. In chapter 6, I focused on the major 
limitations of WES as a diagnostic tool, these being (i) technical limitations and (ii) 
interpretation challenges. Insufficient coverage is one of the main shortcomings of 
WES, as current protocols generally capture no more than 80-90%  of the exons 
even with an average coverage of 90X. In addition, non-coding regions of the 
genome are not captured and sequenced using WES, which may be of particular 
relevance for neurological diseases given the increasing evidence for associations 
between non-coding RNAs and brain development. Ultimately, we still do not know 
all disease-associated genes and hence our filtering strategies are focused on and 
limited to known disease-genes and -pathways. This leaves us with ample challenges 
that are addressed in the last chapter, which is devoted to a discussion of future 
perspectives for NGS applications and how I believe that adding extra layers of 
information would support and accelerate the next stage of NGS in personalized 
medicine. In conclusion, WES-based diagnostic testing is a proven and powerful 
innovation for human genetics the application of which will drive further 


































































































De ongeëvenaarde toename van de capaciteit van op Next-Generation 
Sequencing technologieën (NGS) gebaseerde DNA sequencing maakt een 
kostenefficiënte analyse van het totale genoom of van delen van het genoom 
(exoom of genpanels), voor meerdere monsters in één enkele sequencing run 
met een korte doorlooptijd mogelijk. Echter, ondanks al deze mogelijkheden, 
vormen beperkingen van de techniek, zoals incomplete exon-capturing en 
complexiteit van variantinterpretatie, nog steeds een grote uitdaging voor de 
toepassing van Whole Exome Sequencing (WES) in de kliniek. Het 
onderzoek dat in dit proefschrift wordt gepresenteerd, focust op het gebruik 
van WES voor het ontrafelen van de genetische basis van humane erfelijke 
aandoeningen door (i) screening van een omvangrijke set bekende 
ziekteveroorzakende genen op mutaties; (ii) identificatie van nieuwe 
kandidaat-ziektegenen in genetisch heterogene aandoeningen met 
verschillende mogelijke overervingspatronen; en (iii) ontwikkeling van 
bioinformatica programma’s om via in silico analyses betere mogelijkheden te 
hebben voor de selectie van kandidaatgenen. 
 In hoofdstuk 1 gaven we achtergrondinformatie over NGS 
technieken en een versimpeld overzicht van de verschillende NGS-
processtappen. Dit hoofdstuk introduceert whole genome sequencing, WES, 
ziektespecifieke genpanels en hun toepassingen. De mogelijkheid om WES in 
genoomanalyses toe te passen voor identificatie van causale mutaties in 
ziekten met een extreme locusheterogeniteit is kort beschreven, samen met 
de uitdagingen van data-interpretatie, die noodzakelijk is voor de identificatie 
van de causale mutatie(s) in een achtergrond van niet-pathogene varianten. 
 In hoofdstuk 2 hebben we uiteengezet hoe WES is toegepast als een 
diagnostische benadering bij het vaststellen van een moleculaire diagnose in 
een zeer heterogene groep patiënten met microcefalie en verstandelijke 
beperkingen. We konden een diagnose stellen in 29% van de onderzoeken 
(10 van de 35 families) en vonden mutaties in bekende ziektegenen. Onze 
resultaten lagen in lijn met andere studies over het diagnostisch nut van 
gebruik van WES bij genetisch heterogene aandoeningen. Onze resultaten 
bevestigden dat veel gevallen van microcefalie verklaard worden door 
autosomaal recessieve overerving (7 van de 10 families). We concludeerden 
dat WES een effectieve toepassing is voor de diagnostiek van patiënten met 




 In hoofdstuk 3 is trio-exoomsequencing toegepast om het ziektegen 
te identificeren in een Nederlandse familie met een jongen met familiale 
glucocorticoïd deficiëntie (FGD). Exoomsequencing toonde een nieuwe 
ziekteveroorzakende homozygote mutatie (NM_012343.3:c.1259dupG) in 
NNT aan. De mutatie ligt in exon 9 en veroorzaakt een frameshift die tot een 
vervroegd stopcodon leidt (p.His421Serfs*4). Ook analyseerden we de 
literatuur voor alle gerapporteerde NNT mutaties en hun klinische 
presentatie. De mediaan van de leeftijd waarop de ziekte zich openbaarde 
was 12 maanden (variërend van 3 dagen tot 39 maanden). Er bleek geen 
significant verschil in de leeftijd waarop de ziekte zich openbaarde tussen 
patiënten met NNT mutaties die een vervroegd stopcodon veroorzaken en 
patiënten met andere typen NNT mutaties. Gebaseerd op recente literatuur, 
adviseren wij dat patiënten met door NNT mutaties veroorzaakte FGD 
gescreend worden voor mogelijke gecombineerde mineralocorticoïd 
insufficiëntie en extra-adrenale manifestaties. 
 In hoofdstuk 4 richtten we ons op het identificeren van nieuwe 
ziekteveroorzakende genen voor het L1-syndroom, een X-gebonden 
aandoening, met behulp van een variant WES toepassing. Het is bekend dat 
L1-syndroom kan worden veroorzaakt door mutaties in het L1CAM gen, 
maar zelfs na mutatie-analyse van dit gen blijven veel onopgeloste gevallen 
over. Omdat 95% van alle L1-syndroom patiënten (met en zonder een 
L1CAM mutatie) mannelijk zijn en familiale gevallen meestal een X-
gebonden recessieve overerving laten zien, hebben we ons gefocust op het 
X-chromosoom en een op maat gemaakte X-exoom sequencing uitgevoerd 
in een cohort van 58 patiënten waarin de L1CAM mutatie-analyse negatief 
was. We identificeerden mutaties in 7 patiënten die 5 genen aanwezen als 
mogelijke nieuwe kandidaten voor L1-syndroom: DACH2, TENM1, 
AMER1, PQBP1 en CXorf38. Drie onafhankelijke mutaties in DACH2 
suggereren dit gen als de meest veelbelovende kandidaat voor het L1 
syndroom. Twee overige kandidaatgenen (PQBP1 en AMER1) waren eerder 
al gekoppeld aan ziekten waarvan het klinisch spectrum overlapt met het L1 
syndroom. Hoewel een enkel gen geassocieerd kan zijn met meer dan één 
ziekte, suggereren verschillen in typische fenotypes in L1 syndroom dat het 
minder waarschijnlijk is dat deze aandoeningen een gezamenlijke genetische 




voerden we vervolgens een gerichte analyse van deze 5 kandidaatgenen uit bij 
nog eens 24 patiënten, maar konden geen aanvullende mutaties identificeren. 
Uiteindelijk zullen functionele studies onontbeerlijk zijn om de oorzakelijke 
rol van DACH2, TENM1 en CXorf38 in L1 syndroom definitief vast te 
stellen. Het aantal mutaties in ons cohort wijst erop dat, wanneer causaal, de 
geïdentificeerde genen toch slechts een klein gedeelte van de L1 patiënten 
kunnen verklaren. 
 In hoofdstuk 5 streefden we naar het identificeren van 
onderliggende moleculaire pathomechanismen voor congenitale microcefalie 
(CM) en voorspelden we kandidaatgenen gebaseerd op hun relaties met de 
bekende CM-genen. Een systematisch literatuuronderzoek identificeerde 76 
genen waarvan het zeker is dat ze CM veroorzaken. Hierna voerden we een 
in silico biologische netwerk analyse uit gebaseerd op deze genen, via 
integratie van data van vele verschillende publiek beschikbare biologische 
databases. Onze analyse markeerde bekende biologische processen (d.w.z. 
centrosoom en mitotische spoeldraden, DNA-schade herstel en DNA 
replicatie) als betrokken bij congenitale microcefalie. Verder wees de analyse 
op betrokkenheid van twee biologische functies, telomeerbiologie en het 
tRNA metabolische proces, die minder worden besproken in de literatuur. 
Ook rangschikten we de top 100 genen die zijn gerelateerd aan één van de 
met CM-geassocieerde genen. Evaluatie van deze voorgestelde 
kandidaatgenen toonde aan dat van 7 van de top 100 genen reeds bekend is 
dat ze betrokken zijn bij aandoeningen waarvan microcefalie één van de 
fenotypische kenmerken is. Daarnaast liet vervolgonderzoek van de 93 
overige genen met behulp van de Mouse Genome Informatics database zien dat 
knockout-muizen voor 4 van deze genen cerebrale-cortexafwijkingen of een 
abnormale hersenmorfologie tonen, en waarvan dus verwacht wordt dat ze in 
microcefalie resulteren. Vervolgens bleek uit onderzoek van de Human Gene 
Mutation Database dat 5 extra genen geassocieerd zijn met microcefalie als 
fenotypisch kenmerk. In conclusie leverde onze netwerkstrategie 16 
interessante kandidaatgenen op die we belangrijk achten voor vervolgstudies 
van onopgeloste CM gevallen. Tevens laten deze resultaten het potentieel 
zien van een dergelijke netwerkbenadering als ondersteuning voor het 
ontdekken van genen in genetisch heterogene ziekten. De genen die een 




de 14 genen die in zowel muis als mens belangrijk zijn voor neurologische 
functies of ontwikkelingsfuncties, zouden van bijzonder belang kunnen zijn 
en de voornaamste kandidaten voor onderzoek naar nieuwe CM-genen. 
Eveneens zou vergelijkbaar gebruik van dit in silico framework programma de 
identificatie van nieuwe kandidaatgenen mogelijk maken voor iedere 
zeldzame genetisch heterogene Mendeliaanse ziekte en kan het programma 
bijdragen aan een gedetailleerder mechanistisch begrip van ziekte. 
 Echter, ondanks de veelbelovende WES resultaten in zowel 
diagnostiek als research, blijven er onopgeloste gevallen over. In hoofdstuk 
6 ging ik in op de belangrijkste beperkingen van WES als diagnostische tool. 
Dit zijn (i) technische beperkingen en (ii) uitdagingen met betrekking tot de 
interpretatie. Onvoldoende dekking is een van de grootste tekortkomingen 
van WES, aangezien bij huidige protocollen zelfs met een gemiddelde 
coverage van 90X of hoger meestal niet meer dan 80-90% van de exonen 
goed analyseerbaar zijn. Daarnaast worden met WES niet-coderende 
genomische gebieden niet verrijkt en gesequenced, wat van bijzonder belang 
kan zijn voor neurologische ziekten, gegeven het groeiende bewijs voor 
associaties tussen niet-coderend RNA en hersenontwikkeling. Tenslotte 
kennen we nog niet alle ziektegerelateerde genen en dus zijn onze 
filterstrategieën gericht op, en beperkt tot bekende ziektegenen en ziekte-
processen. Dit levert zeker uitdagingen, die worden besproken in het laatste 
hoofdstuk, dat is gewijd aan een discussie van toekomstperspectieven voor 
NGS-toepassingen en hoe ik geloof dat toevoeging van extra lagen 
informatie de volgende stap van NGS in personalized medicine zou 
ondersteunen en versnellen. Concluderend: op WES gebaseerd diagnostisch 
testen is een bewezen en krachtige innovatie, waarvan de toepassing verdere 
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